From DEPARTMENT OF ONCOLOGY-PATHOLOGY
Karolinska Institutet, Stockholm, Sweden

CONNECTING VIRAL ONCOPROTEINS TO MICRORNA, AUTOPHAGY AND METABOLISM IN MERKEL CELL CARCINOMA

Satendra Kumar

Stockholm 2019

Connecting viral oncoproteins to microRNA, autophagy and metabolism in Merkel cell carcinoma
THESIS FOR DOCTORAL DEGREE (Ph.D.)

The public defence of the dissertation will be held at the Ulf von Euler Auditorium, BioClinicum J3:06, Solnavägen 30, Karolinska University Hospital, Solna on August 30th, 2019 at 9:30 a.m.

By

Satendra Kumar

Principal Supervisor:
Associate Professor Weng-Onn Lui
Karolinska Institutet
Department of Oncology-Pathology

Co-supervisor(s):
Professor Catharina Larsson
Karolinska Institutet
Department of Oncology-Pathology

Associate Professor Anders Höög
Karolinska Institutet
Department of Oncology-Pathology

Dr. Viveca Björnhagen
Karolinska University Hospital
Department of Reconstructive Plastic Surgery

Associate Professor Hong Xie
Tianjin Medical University
Department of Pathogen Biology

Opponent:
Professor Stefan Schwartz
Lund University
Department of Laboratory Medicine

Examination Board:
Associate Professor Ning Xu Landén
Karolinska Institutet
Department of Medicine, Solna

Associate Professor Gerald McInerney
Karolinska Institutet
Department of Microbiology, Tumor and Cell Biology

Associate Professor Tanel Punga
Uppsala University
Department of Medical Biochemistry and Microbiology

Institution för onkologi-patologi

Connecting viral oncoproteins to microRNA, autophagy and metabolism in Merkel cell carcinoma

AKADEMISK AVHANDLING
som för avläggande av medicine doktorsexamen vid Karolinska Institutet offentligen försvaras i BioClinicum J3:06 Ulf von Euler, Solnavägen 30, Karolinska Universitetssjukhuset, Solna

Fredagen den 30:e augusti 2019, kl 09.30

av
Satendra Kumar
MSc

Huvudhandledare:
Associate Professor Weng-Onn Lui
Karolinska Institutet
Department of Oncology-Pathology

Bihandledare:
Professor Catharina Larsson
Karolinska Institutet
Department of Oncology-Pathology

Associate Professor Anders Höög
Karolinska Institutet
Department of Oncology-Pathology

Dr. Viveca Björnhagen
Karolinska University Hospital
Department of Reconstructive Plastic Surgery

Associate Professor Hong Xie
Tianjin Medical University
Department of Pathogen Biology

Fakultetsopponent:
Professor Stefan Schwartz
Lund University
Department of Laboratory Medicine

Betygsnämnd:
Associate Professor Ning Xu Landén
Karolinska Institutet
Department of Medicine, Solna

Associate Professor Gerald McInerney
Karolinska Institutet
Department of Microbiology, Tumor and Cell Biology

Associate Professor Tanel Punga
Uppsala University
Department of Medical Biochemistry and Microbiology

Stockholm 2019

"When you stay on purpose and refuse to be discouraged by fear, you align with the infinite self, in which all possibilities exist."

Wayne Dyer

To my family, especially my parents, and friends

ABSTRACT

Merkel cell carcinoma (MCC) is an aggressive type of skin cancer. Around 80% of MCCs harbor an integrated Merkel cell polyomavirus (MCPyV) genome with a mutation in the large T antigen (LT) gene, leading to expression of truncated LT. It is evident that the viral truncated LT and small T antigen (sT) play important roles in MCC tumorigenesis. Yet, the molecular mechanisms how these viral oncoproteins contribute to MCC development remain unclear. The studies presented in this thesis aim to further our understanding of the functional role of these MCPyV oncoproteins in MCC tumorigenesis.

In **Paper I**, we demonstrated that MCPyV T-antigens induce *miR-375*, *miR-30a-3p* and *miR-30a-5p* through the DnaJ domain of the viral T-antigen. These miRNAs could target multiple autophagy genes (*ATG7*, *SQSTM1* and *BECN1*) and suppress autophagy in MCC cells. Additionally, we showed that both sT and truncated LT also suppress autophagy, but not the full-length LT. Inhibition of autophagy, but not pan-caspases, could rescue cell death induced by the mTOR inhibitor Torin-1, suggesting that suppression of autophagy is crucial for cell survival in MCC.

In **Paper II**, we found paranuclear dot-like staining of c-KIT in MCPyV positive (MCPyV+) MCC cell lines and tumor samples. Mechanistically, we showed that MCPyV truncated LT induces paranuclear retention of c-KIT through its Vam6p binding site. Our results also revealed that c-KIT interacts with BECN1. Silencing of c-KIT increased autophagy and apoptosis, and decreased LT expression. Inhibition of autophagic degradation in c-KIT depleted cells restored the LT expression, suggesting the importance of autophagy suppression to sustain the expression of viral oncoprotein and cell survival.

In **Paper III**, we showed that overexpression of *miR-375* suppressed cell growth and migration in MCPyV- MCC cell lines, while suppression of *miR-375* decreased cell growth and increased apoptosis in MCPyV+ MCC cell lines. The expression of LDHB, a target of *miR-375*, was inversely correlated with *miR-375*. Silencing of LDHB decreased cell growth in MCPyV- MCC cells, but rescued cell growth suppression resulted from *miR-375* inhibition in MCPyV+ MCC cells. Our findings suggest that *miR-375* regulation of LDHB plays distinct roles in MCPyV+ and MCPyV- MCC.

In **Paper IV**, we demonstrated that MCPyV T-antigens reduce LDHB expression and promote glycolysis in MCC. Overexpression of LDHB reduced cell viability and increased apoptosis in MCPyV+ MCC cells. Ectopic expression of LDHB reversed the growth-promoting effect of MCPyV oncoproteins. Inhibition of glycolysis reduced cell growth in MCPyV+ MCC cells, while inhibition of mitochondrial respiratory activity inhibited cell growth in MCPyV- MCC cells. Our findings suggest that MCPyV+ and MCPyV- MCC cells are dependent on different energy metabolism for cell growth.

Overall, this thesis work highlights the diverse functions of MCPyV oncoproteins and their involvement in regulating miRNA expression, autophagy and energy metabolism.

LIST OF SCIENTIFIC PAPERS

This thesis is based on the following papers, which will be referred to in the text by their Roman numerals:

I. **Satendra Kumar**, Hong Xie, Hao Shi, Jiwei Gao, Carl Christofer Juhlin, Viveca Björnhagen, Anders Höög, Linkiat Lee, Catharina Larsson, Weng-Onn Lui. Merkel cell polyomavirus oncoproteins induce microRNAs that suppress multiple autophagy genes.
Int J Cancer, 2019 Jun 10. doi 10.1002/ijc.32503.

II. Hao Shi, Linkiat Lee, Jiwei Gao, **Satendra Kumar**, Hong Xie, Vladana Vukojevic, Filip Farnebo, Viveca Björnhagen, Anders Höög, Carl Christofer Juhlin, Catharina Larsson, Weng-Onn Lui. Merkel cell polyomavirus oncoprotein induces paranuclear retention of c-KIT suppressing autophagy through interaction with Beclin-1.
Manuscript

III. **Satendra Kumar**, Hong Xie , Patrick Scicluna, Linkiat Lee, Viveca Björnhagen, Anders Höög, Catharina Larsson, Weng-Onn Lui. *MiR-375* regulation of LDHB plays distinct roles in polyomavirus-positive and -negative Merkel cell carcinoma.
Cancers (Basel), 2018 Nov 14, 10: E443.

IV. **Satendra Kumar**, Patrick Scicluna, Hao Shi, Jiwei Gao, Viveca Björnhagen, Anders Höög, Catharina Larsson, Weng-Onn Lui. Merkel cell polyomavirus oncoproteins suppress LDHB and promote glycolysis for cell growth.
Manuscript

CONTENTS

LIST OF ABBREVIATIONS

aa	Amino acid
AGO	Argonaute protein
ALTO	Alternate frame of the large T open reading frame
CDS	Coding sequence
CK20	Cytokeratin 20
DNA	Deoxyribonucleic acid
dsDNA	Double-stranded deoxyribonucleic acid
dsRNA	Double-stranded ribonucleic acid
ECAR	Extracellular acidification rate
Endo H	Endonuclease H
ER	Endoplasmic reticulum
GFP	Green fluorescence protein
GIST	Gastrointestinal stromal tumor
HBV	Hepatitis B virus
HCV	Hepatitis C virus
HPV	Human papilloma virus
IF	Immunofluorescence
IP	Immunoprecipitation
LSD	Large T antigen stabilization domain
LT	Large T antigen
MCC	Merkel cell carcinoma
MCPyV	Merkel cell polyomavirus
miRNA	microRNA
MUR1	MCPyV unique region 1
MUR2	MCPyV unique region 2
NCCR	Non-coding control region

NFP	Neurofilament protein
NLS	Nuclear localization signal
OCR	Oxygen consumption rate
ORF	Open reading frame
ORR	Objective response rate
PCR	Polymerase chain reaction
PD-1	Programmed cell death protein 1
PD-L1	Programmed cell death ligand 1
PNGase F	Peptide:N-glycosidase F
pre-miRNA	Precursor microRNA
pri-miRNA	Primary microRNA
RFP	Red fluorescence protein
RISC	RNA induced silencing complex
RNA	Ribonucleic acid
RT-qPCR	Reverse transcription-quantitative PCR
SCF	Stem cell factor
SCLC	Small cell lung carcinoma
shRNA	Short hairpin RNA
siRNA	Small interfering RNA
sT	Small T antigen
UTR	Untranslated region
UV	Ultra-violet

1 INTRODUCTION

1.1 MERKEL CELL CARCINOMA

Merkel cell carcinoma (MCC) is a neuroendocrine skin cancer, which was first described by Toker in 1972 [1]. About 90% of MCCs arise in sunlight-exposed areas, mainly head and neck, while some are also found on the trunk and genitals [2]. MCC mainly occur in the older age group (average age, 77 years) and in immunosuppressed patients. The incidence increased almost four times in the last two decades in the United States [3–5] and almost doubled in Sweden from 1993 to 2012 [6]. MCC is a highly metastatic disease; it has approximately 40% disease-specific mortality [4]. Miller *at al* reported that around half of the patients from a cohort of 179 patients with metastatic disease had a median survival of approximately 9 months [7].

MCC is believed to arise from Merkel cells, a type of mechanoreceptor cell present in the stratum basal areas of the epidermis, because they share some common immunophenotypes (such as cytokeratin 20, synaptophysin and several endocrine markers) and the presence of neurosecretory granules [8,9]. However, several pieces of evidence argue against this. For example, neural cell adhesion molecule L1 (CD171) and tyrosine kinase receptor c-KIT are detected in most MCCs but not in Merkel cells [10]. Furthermore, Merkel cells are differentiated and post-mitotic, while MCCs are highly proliferative [11]. Interestingly, MCCs commonly express pre-/pro-B specific expression markers (TdT and PAX5) and immunoglobulins, suggesting that early B cells may represent putative progenitors of MCC [12].

About 80% of MCCs are infected with Merkel cell polyomavirus (MCPyV), which was discovered by Moore and Chang in 2008 [13]. Despite that MCPyV is widespread in the general population, integration of mutated viral DNA into the host genome and expression of viral T-antigens are only detected in MCCs [14]. Importantly, the viral T-antigens are required for neoplastic transformation and maintenance of MCC cell growth [15], supporting their important roles in the pathogenesis of MCC. An introduction of MCPyV T-antigens and their involvement in MCC tumorigenesis is described in Chapter 1.2. Besides MCPyV, ultra-violet (UV) exposure is another etiology of MCC. MCPyV and UV-associated MCCs are molecularly distinct (for details, please refer to Chapter 1.1.2).

1.1.1 Diagnosis, prognosis and treatment of MCC

Three types of MCC are recognized based on histological features: intermediate, small cell and trabecular [16]. The trabecular type is a well-differentiated form with a better prognosis, while the small cell type is undifferentiated with worse prognosis. The intermediate type has more mitotic activity [4,17].

MCC is generally characterized by expressions of cytokeratin 20 (CK20) with a paranuclear dot-like staining pattern and neuroendocrine markers such as neuron-specific enolase (NSE), synaptophysin and chromogranin A [18]. Most MCCs are MCPyV positive (MCPyV+), therefore immunostaining of MCPyV LT can be used to identify virus-associated

MCCs. However, the virus-negative MCCs are hard to be diagnosed and differential diagnosis is necessary to distinguish MCC from other common neuroendocrine tumors, such as small cell lung carcinoma (SCLC), melanoma and cutaneous lymphoma (Table 1).

Table 1. Immunohistochemical staining used for differential diagnosis of MCC

	CK20	CK7	NSE	TTF1	S100	LCA
Merkel cell carcinoma	+	-	+	-	-	-
Melanoma	-	-	-	-	+	-
Small cell lung carcinoma	-	+	+	+	-	-
Cutaneous lymphoma	-	-	-	-	-	+

CK20, cytokeratin 20; CK7, cytokeratin 7; NSE, neuron-specific enolase; TTF-1, thyroid transcription factor 1; LCA, leucocyte common antigen. + and – refer to presence or absence of the staining, respectively. Adapted from Jaeger *et al* (2012) [19].

Based on the American joint committee on cancer (AJCC) and the European consensus-based interdisciplinary guidelines, clinical/ histological features, distant tissue involvement and staging system should be employed for prognostic classification of MCC [17,20,21]. Larger primary tumor size is associated with an increased risk of metastasis and sentinel lymph node biopsies are required for all the patients with primary tumor [22]. According to Surveillance, epidemiology and end results (SEER) data from 3870 MCC cases, 10-years survival rate was less in male (50%) than female (65%) patients [4]. Patients with local disease had 64% of five years survival rate, as compared to 40% in regional nodal disease and 18% in metastatic disease [23,24]. However, there were no significant differences observed in survival rate between different age groups [4]. Till date, no robust prognostic marker has been reported for MCC patients, however some reports showed that lack of lymphatic vessels invasion and T-cell infiltration can be used as a good prognosis indicator for MCC patients [20,25,26].

AJCC classified MCC staging based on three important indicators: tumor size and invasiveness of the primary tumor (T), degree of lymph node involvement (N) and metastatic state (M). Yiengpruksawan *et al* provided the first staging system for MCC, which defined tumor restricted to the skin as stage I, nodal metastasis as stage II, and distant metastasis as stage III and stage IV [27]. The overall staging for MCC is shown in Table 2.

Table 2. MCC staging and prognosis based on national cancer database

Stage	T	N	M	5-year survival
0	TIS	N0	M0	
IA	T1	pN0	M0	79%
IB	T1	cN0	M0	60%
IIA	T2/T3	pN0	M0	58%
IIB	T2/T3	cN0	M0	49%
IIC	T4	N0	M0	47%
IIIA	Any T	N1a	M0	42%
IIIB		N1b/N2	M0	26%
IV		Any N	M1	18%

T = primary tumor, N = degree of lymph node involvement, M = metastatic state, TIS = in situ primary tumor, pN0 = nodes negativity by pathologic examination, cN = nodes clinically detectable. Adopted from Lemos *et al* (2012) [17].

The choice of treatments for MCC depends on the stage of the tumor and health of the patient. Generally, wide surgical excision with 1-2 cm margins, followed by radiotherapy is used for treatment of the primary tumor. Chemotherapy regimens such as platinum-based, taxanes, anthracyclines and etoposide are considered as systemic therapeutic agents for treatments of advanced MCC. However, these drugs have less durable responses and no significant effects on survival rate. Chemotherapy is now considered to play a palliative role [28]. In the past few years, several new targeted therapies have been investigated as treatment options for treatment of advanced and metastatic MCC. For examples, YM155, a small molecule inhibitor targeting survivin, induces cell death in MCPyV+ MCC cell lines and xenograft [29,30]. ABT-263 is a potent inhibitor for the anti-apoptotic Bcl-2 family members, which induces apoptosis in MCC cell lines and xenograft [31,32]; however, this drug did not show any significant effect in a phase II trial [33]. Although *KIT* mutations are rarely found in MCC, its overexpression has been observed in MCC tumors [34,35]. Several MCC patients have been successfully treated with imatinib, a small molecule tyrosine kinase inhibitor that blocks c-KIT activation [36–38]. However the results from a phase II trial of imatinib in MCC were disappointing since a majority of patients progressed within 1 to 2 cycles of treatment, indicating its limited clinical benefit for MCC patients [39]. Furthermore, Pazopanib, which can inhibit several receptor tyrosine kinases including, FGFR, PDGFR, VEGFR and c-KIT, has demonstrated some clinical beneficial effects in a single MCC patient [40].

Both MCPyV+ and MCPyV- MCC tumor cells express programmed cell death ligand 1 (PD-L1), with PD-L1 expression being more frequently detected in MCPyV+ tumor cells than MCPyV- MCC tumor cells [41]. The PD-L1 expression pattern in MCC tumor cells supports the ideas to use PD-1 signaling pathways for targeted therapy in advanced MCC patients. Several phase II trials are ongoing to use anti-PD-1 and/or anti-PD-L1 checkpoint inhibitors for MCCs patients. These inhibitors showed durable response in advanced MCC patients pre-treated with chemotherapy [41–43]. For example, avelumab (anti-PD-L1 antibody) was used to treat 88 MCC patients with metastatic disease and found that 32.8 % had objective response rate (ORR), including complete and durable response in 9.1 % patients,

which were also associated with improved quality of life [43]. In another study with pembrolizumab (anti-PD-1 antibody) as a first line therapy, 56 % achieved ORR, including complete response in 15.4 % of the patients [41]. Presently, these two checkpoint inhibitors (avelumab and pembrolizumab) are approved by the Food and Drug Administration (FDA) to treat MCC.

1.1.2 Mutations, cancer pathways and immune profiles

MCPyV is an established etiology for MCC, and the remaining 20% of MCPyV- MCCs are regarded as having a UV radiation etiology. These two groups are also known to display different genomic mutation profiles. While MCPyV+ tumors exhibit less somatic mutations and copy number alterations, MCPyV- tumors have higher mutational burden. MCPyV+ tumors have around 25-fold less mutation frequency compared to UV-associated tumors[44–46]. Notably two key tumor suppressor genes, *RB1* and *TP53*, are frequently mutated in UV-associated MCCs, but not in MCPyV+ MCCs; however, their functions are inactivated by MCPyV T-antigens in MCPyV+ tumors [45,47–50]. In addition, MCPyV- MCCs carry inactivating mutations in genes involved in several cancer pathways, such as PI3K/Akt/mTOR, Notch, Wnt signaling, DNA damage repair and chromatin modifying pathways [44,46,48,51].

Based on global mRNA profiles, gene expression patterns in MCC are distinct from other primary cutaneous carcinomas [52]. As compared to squamous cell carcinoma, MCCs had higher levels of *CK20*, chromogranin A, synaptophysin, *AKT3*, *FYN*, *RAB3B*, *JUND*, *FEV*, *SOX2*, *BCL2*, *MYCL1*, *VEGFA*, *GPC3*, *ATOH1*, *HIP1* and *c-KIT*. On the other hand, genes involved in Hedgehog signaling, including *GL1*, *GLI2*, *PTCH1* and *PTCH2*, were higher expressed in basal cell carcinoma compared to MCC. Notably, the gene expression signatures of MCPyV+ and MCPyV- MCCs were also distinct [52]. Among the differentially expressed genes, MCPyV- tumors had higher expressions of transcripts involved in Notch signaling (such as *DLL1*, *CTBP2*, *HES1*, *JAG2* and *JAG1*) and receptor tyrosine kinase signaling (*e.g. FGFR2*, *VEGFA*, *PDGFA*, *FGF14*, *FGF11* and *FGF9*). In addition, increased expression of immune response genes were also observed in MCPyV+ as compared to MCPyV- MCCs [52]. Importantly, the immune response gene signature, especially genes associated with cytotoxic CD8 lymphocytes, is associated with a good prognosis in MCC [53]. In line with the transcriptome analysis, tumor-infiltrating immune cells are associated with favorable survival in MCC [26,53–55]. Although several immune response genes are higher expressed in MCPyV+ than MCPyV- MCCs, both MCPyV+ and UV-associated MCCs are immunogenic [56]. It is now clear that MCC can evade the immune response using the PD-1/PD-L1 immune-checkpoint pathway. Most MCC tumors express PD-L1, which binds to its receptor PD-1 on T cells [48,57], leading to inhibition of T cell killing of tumor cells. Therefore, targeting the PD-1/PD-L1 immuno-checkpoint has become a promising therapy for MCC patients.

1.2   MERKEL CELL POLYOMAVIRUS (MCPyV)

MCPyV is a circular double-stranded DNA (dsDNA) virus, which belongs to the Polyomaviridae family. The genome is about 5.4 kb and harbors early and late regions separated by a non-coding control region (NCCR). The early region contains the T-antigen gene locus, the late region encodes the capsid proteins and the NCCR contains the bipartite origin of replication. Besides viral proteins, MCPyV also contains gene for a single microRNA (*mcv-miR-M1*) which is located in an antisense direction to the early region that negatively regulates early transcripts and limits viral DNA replication [58].

1.2.1 MCPyV T-antigens

The T-antigen locus generates multiple alternatively spliced transcripts, namely large T (LT), small T (sT), 57 kT and alternate frame of the large T open reading frame (ALTO). Domain structures of various T-antigens are shown in Figure 1, and their functions are summarized in the following sections.

1.2.1.1   Large T-antigen

The LT of MCPyV includes several conserved features (such as DnaJ, Rb binding motif, origin binding domain (OBD), zinc finger and ATPase/helicase) and two unique regions called MCPyV unique regions 1 and 2 (MUR1 and MUR2). The DnaJ domain comprises of the CR1 (LXXLL) and the Hsc70 binding (HPDKGG) motifs, which is required for viral replication [58] and growth promoting activity [59]. The Rb binding motif (LXCXE) is flanked by MUR1 and MUR2. This motif is highly conserved across polyomaviruses and is required for cell cycle progression through up-regulation of E2F target genes and survivin [60,61]. MUR1 has a Vam6p binding site, in which the interaction disrupts lysosomal trafficking by sequestration of Vam6p to the cell nucleus [62]. The functional role of nuclear sequestration of Vamp6 remains unclear, however it is known that Vam6p can regulate MCPyV replication *in vitro* [63], and it is not essential for promoting cell growth [60]. MUR2 has a nuclear localization signal (NLS, RKRK motif) [64]. The NLS was initially found to be conserved in MCC tumors and regarded as functionally important in MCC pathogenesis, but recent findings showed that this motif is not always preserved in the MCC-specific truncated LT and is not required for the growth promoting activity of LT [60]. Several key domains in the carboxyl-terminal of LT are required for viral replication. The OBD recognizes and binds the viral origin of replication in the NCCR, the zinc finger motif and the ATPase/helicase domains are required for replication initiation. Although the helicase domain of SV40 directly binds to p53, this domain in MCPyV cannot interact with p53 [64,65].

1.2.1.2   Small T antigen

MCPyV LT and sT share exon 1 of the T antigen, therefore they have the common DnaJ domain in the amino-terminal. The carboxyl-terminal of sT carries unique features, including LT-Stabilization Domain (LSD), and protein phosphatase 2A and 4C (PP2A and PP4C) binding sites. As aforementioned, the DnaJ domain of LT is required for viral replication, however mutation of this domain in sT does not affect MCPyV replication [59]. The function of

this domain remains elusive. A major feature of MCPyV sT is the LSD, which has been shown to inhibit Fbw7 ubiquitin ligase, thereby stabilizing LT, c-Myc and cyclin E. Stabilization of these proteins is important for viral replication and transformation [66]. The LSD also targets 4E-BP1 and prevents the turnover of its hyperphosphorylated form, which increases eIF4F activity and in turn, mitotic-dependent protein translation [15,66].

The PP2A domain is known to be the primary function of sT in other polyomaviruses such as SV40, in which sT binds PP2A by competing with B subunit (one of the subunits in the PP2A heterotrimeric complex) and inhibits Akt-mTOR signaling, leading to cell cycle progression, survival and differentiation [67–69]. However, PP2A binding of MCPyV sT is not required for transformation activity [32,70]; this is likely due to limited B subunit targeting in the MCPyV sT compared to the sT in SV40 and other polyomaviruses. PP4C and/or PP2A Aβ of MCPyV sT interact with NF-kB essential modulator (NEMO) protein and disrupt host cell inflammatory signaling mediated by NF-kB [71]. The PP4C site is also important for promoting cell motility and migration by destabilization of microtubules through inhibition of stathmin phosphorylation, a key microtubule binding protein [72,73]. MCPyV sT induces cell motility through Rho-GTPase, which induces filopodium formation in MCC [74]. This effect may explain the highly metastatic nature of MCC tumors. Additionally, sT induces aerobic glycolysis through induction of monocarboxylate transporter (MCT1) that regulates MCC cell proliferation and viability [75]. sT can also induce motility and invasiveness by inducing Cl^--channel proteins CLIC1 and CLIC4 [74] or cellular sheddase proteins ADAM 10 and ADAM 17 [76].

1.2.1.3 57 kT and ALTO

The 57 kT is an alternatively spliced T-antigen of 432 amino acids. It shares the first 332 and the last 100 amino acids with LT, including the DnaJ domain, Rb binding site, MURs and nuclear localization signal, but lacks the OBD and most of the helicase domain. Although the functional role of the 57 kT is still unclear, Cheng *et al* showed that the full-length 57 kT and the carboxyl-terminal of 100 residues encoded from exon 3 of the 57 kT has a growth inhibition function [77]. ALTO is encoded by an alternative ORF of LT, which is evolutionarily related to the middle T antigen of murine polyomavirus. ALTO is expressed during viral replication, however it is not essential for MCPyV genome replication *in vitro* [78] and cell growth in MCC cells [60].

Figure 1. Functional domains of various MCPyV T-antigens. The T-antigen locus of MCPyV encodes four spliced transcripts. LT is 816 amino acids in size, containing DnaJ domain, retinoblastoma (Rb) binding motif, MCPyV unique regions 1 and 2 (MUR1 and MUR2), origin binding domain (OBD), zinc finger motif and ATPase/helicase. LT mutations are commonly found in MCC tumors, in which the mutation sites are located downstream of the Rb binding site. sT, 186 amino acids in length, shares the same DnaJ and Hsc70 binding domain of LT, and carries unique features LT-Stabilization Domain (LSD), protein phosphatase 2A and 4C (PP2A and PP4C) binding sites at its carboxyl-terminal. 57 kT, 432 amino acids in length, also shares the DnaJ domain with LT and sT, and contains the MUR1 region, Rb binding domain and exon 3 of LT. ALTO encodes 200 residues of MUR region of LT and OBD, which is closely related to middle T antigen of murine polyomavirus.

1.2.2 MCPyV integrations, mutations, expressions and functions in MCC

As aforementioned, MCPyV infection is widespread in the general population. However, the tumorigenic MCPyV can be distinguished from the non-tumorigenic ones based on the presence of viral DNA integration and LT mutations. MCPyV has been shown to monoclonally integrate into the genome of MCC tumors [14,79,80]. The viral integration sites have been identified within or in the vicinity of several cellular genes, including *PTPRG*, *GMDS*, *DENND1A*, *SNAT1*, *IL20RA*, *SRD5A2L2* and *MYC*; however no recurrent viral integration site has been identified.

All MCPyV+ MCC tumors harbor LT mutations (point mutations or small indels) that lead to expression of truncated LT (Figure 1). These mutants retain Rb binding but eliminate

viral replication capacity. Besides the truncated LT, most MCPyV+ MCC tumors also express intact sT [15], and some has truncated ALTO [78]. Despite the functional role of truncated ALTO remains to be characterized, both truncated LT and sT are required for cellular transformation and tumorigenesis *in vitro* and *in vivo* [15,32,77,81–83]. Furthermore, these T-antigens are also necessary for the maintenance of cell growth in MCPyV+ MCC cells [84].

1.3 MICRORNA

microRNA (miRNA) was first discovered in *Caenorhabditis elegans* (*C. elegans*) by the Ambros and Ruvkun groups [85,86]. They found that *lin-4* binds to its complementary sequence in the 3´ untranslated region (UTR) of *lin-14* and down-regulate its translation. However, the miRNA field only started to emerge after the discovery of the highly conserved miRNA called *lethal-7 (let-7)* in 2000 [87]. *Let-7* was detected in a wide range of animal species, including human [88]. This finding inspired several groups to search for miRNAs in different organisms. In 2001, about 100 miRNAs had been discovered in fly, worm and human [89–91].

1.3.1 Biogenesis and function

The biogenesis of miRNAs starts from the transcription of the miRNA-encoding gene by RNA polymerase II, this primary transcript is called primary miRNA (pri-miRNA) [92,93]. This pri-miRNA is self-complementary and forms a hairpin structure with some imperfect base pairing [94], which is captured by an enzyme complex of Drosha (RNase type-III) and DiGeorge syndrome critical region gene 8 (DGCR8) that processes the pri-miRNA into the precursor miRNA (pre-miRNA) with a 2-nucleotide overhang at the 3´end; this complex is also termed as microprocessor complex [92,95–97]. After that, the pre-miRNA is transported from nucleus to the cytoplasm via exportin-5 (XPO5) in association with RAN-GTP. In the cytoplasm, the pre-miRNA is further processed by another dsRNase type-III enzyme called Dicer [95,98]. Dicer has N-terminal helicase activity, which helps in the processing of a double-stranded miRNA duplex. This miRNA duplex is actively incorporated into RNA induced silencing complex (RISC), resulting in the formation of RISC loading complex (RLC) [99]. Subsequently one strand of the miRNA duplex, called guide strand, is incorporated into the complex, while the other strand (passenger strand) is removed from the complex [100]. The miRNA biogenesis is schematically illustrated in Figure 2.

Figure 2. An overview of miRNA biogenesis and its mode of action. miRNA is transcribed from the host miRNA gene by RNA polymerase II and formed pri-miRNA, which is further processed by Drosha and DGCR8 protein complex to form pre-miRNA and then transported to the cytoplasm from nucleus by exportin 5. DICER and TARBP2 protein complex further processes the pre-miRNA into mature miRNA, which is then loaded into the RISC complex. miRNA binds to specific mRNA and degrades its target via translation repression or mRNA degradation depending on the degree of sequence complementarity between miRNA and mRNA.

miRNAs mostly functions by complementary base pairing with 3'UTR, but occasionally in the 5´UTR or coding sequence of the target mRNAs [101–104]. These interactions can either lead to degradation of target mRNA or inhibition of translation, depending upon the degree of base pairing. If there is more base-pairing or complete base pairing to the target mRNA, it is more likely to be degraded; in case of less number of base pairing or incomplete base pairing, it will lead to translational inhibition [105–107].

1.3.2 miRNAs in virus-induced tumorigenesis

Several human viruses are known to cause cancers, such as Epstein-Barr virus (EBV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human T-lymphotropic virus I (HTLV-I), human papillomavirus (HPV), Kaposi's sarcoma herpesvirus (KSHV) and MCPyV [108–115]. Among these, some are known to express viral oncogenes that directly contribute to cancer development through regulation of tumor suppressor pathways (such as Rb and p53), as well as other common targets that play important roles in tumorigenesis, including NF-κB, AKT-mTOR, autophagy and immune evasion. In this section, several examples of how miRNAs are involved in viral oncogenesis are described.

1.3.2.1 Hepatitis B/C (HBV or HCV)-associated hepatocellular carcinoma

Chronic infection with HBV and/or HCV is one of the known factors that contribute to hepatocellular carcinoma development. Although the mechanisms by which the viruses induce cellular transformation and tumorigenesis remain unclear, several pieces of evidence indicate the involvement of miRNAs in the pathogenesis of this tumor type. Several cellular miRNAs are known to regulate HBV and HCV gene expression and replication. For example, *miR-199a-3p*, *miR-210*, *miR-92a*, *miR-20a* and *miR-224* directly regulate HBV genes that reduce viral replication [116–118], while some miRNAs (*miR-1*, *miR-372/373*, *miR-141* and *miR-122*) can modulate HBV replication by targeting the cellular genes that regulate viral replication, such as farnesoid X receptor α, nuclear factor I/B, peroxisome proliferator-activated receptor alpha and cyclin G1 [119–121]. For HCV, *miR-122* binds directly to HCV RNA, which enhances HCV translation and replication [122]. Inhibition of *miR-122* effectively blocks HCV replication in human and chimpanzee [123; 124]. Additionally, *miR-141*, *miR-199a*, *miR-29*, *let-7b*, *miR-130a*, *miR-27a*, *miR-196* and *miR-448* can also regulate HCV replication through direct interaction of HCV RNA or indirectly via cellular targets [125–131].

Besides viral replication, viral proteins have also been shown to regulate miRNA expression that promotes tumorigenesis. For example, hepatitis B virus protein X (HBx, one of the transactivators that plays a crucial role in the hepatocellular carcinogenesis) represses *miR-148a*-mediated suppression of HPIP (a key regulator of tumorigenesis) that enhances tumorigenesis in a mouse model of hepatocellular carcinoma [132]. HBx also modulates multiple miRNAs, including *miR-216b*, *miR-373*, *miR-15b* and *miR-205*, while HBV preS2 (another transactivator of HBV) represses *miR-338-3p* that lead to the development or progression of hepatocellular carcinoma [133–138].

1.3.2.2 Human papillomavirus (HPV)-associated cervical cancer

Persistent infection with high-risk human papillomavirus (HPV), such as HPV 16 and 18, is a cause of cervical cancer [139]. This virus encodes two key oncoproteins, *i.e.* E6 and E7, which promote tumorigenesis by inhibiting the p53 and RB tumor suppressor, respectively. These two viral oncoproteins are also known to regulate miRNAs that play crucial roles in oncogenic pathways [139].

The high-risk HPV E6 has been shown to suppress several miRNAs resulting from the E6-mediated destabilization of p53, such as *miR-34a*, *miR-23b* and *miR-145* [139–141]. These miRNAs are transcriptionally activated by p53 and play an important role in p53 tumor suppression. The HPV E7 interacts with Rb and inhibits its binding to E2F, thereby promoting cell cycle progression through E2F-mediated transcription [142]. Similar to the E6-mediated effect of p53-regulated miRNAs, HPV16 E7 has been shown to regulate *miR-15b* [143], which is a transcriptional target of E2F1 [144]. Additionally, HPV16 E7 also induces *miR-27b* that regulates cell proliferation and apoptosis in cervical cancer cells through polo-like kinase 2 [145], and suppresses *miR-203*-mediated repression of p63 upon epithelial differentiation [146]. A few miRNAs have been implicated to regulate HPV DNA replication or gene expression. *miR-203*, *miR-145* and *miR-125b* can inhibit HPV genome amplification [146–148], while *miR-375*, *miR-875* and *miR-3144* directly suppress HPV transcripts [149].

1.3.2.3 *MCPyV-associated MCC*

As aforementioned, MCPyV plays an important role in MCC tumorigenesis. Our group previously identified specific miRNAs associated with MCPyV status, tumor metastasis and disease-specific survival in MCC patients [150], suggesting the importance of miRNAs in MCC development and progression. Importantly, *miR-375* is highly abundant and specific for MCC and its serum levels correlate with tumor burden in MCC [151]. However the functional role of miRNAs in MCC pathogenesis is still poorly understood. To date, only two miRNAs, *miR-203* and *miR-375*, have been functionally characterized in MCC. *miR-203* can inhibit cell growth and induce cell cycle arrest in MCPyV- MCC cells [150], while *miR-375* can regulate neuroendocrine differentiation, cell growth, autophagy and glycolysis in MCC cells [152–154]. In addition, Theiss *et al* demonstrated that *mcv-miR-M1* (a miRNA encoded by the MCPyV) suppresses early viral transcripts and limits DNA replication of viral episomes [155].

1.4 AUTOPHAGY

About 50 years ago, the term "autophagy" was given for the first time by Duve *et al* [156]. It is a Greek word, meaning self-eating property. Autophagy is a cellular degradation process required for development, differentiation, survival and maintaining the homeostasis of the cells [157]. Autophagy is mainly divided into three types, namely macro-autophagy, micro-autophagy and chaperone-mediated autophagy (CMA) [158], which differ on the basis of transportation of cytoplasmic material to the lysosomes. Macro-autophagy is the most common type of autophagy, which involves double membrane vesicles called autophagosomes containing cellular proteins and damaged organelles which are subsequently delivered to lysosomes for degradation [159]. Micro-autophagy involves projections of the lysosomal membrane that capture the cargo molecules, and CMA involves chaperone proteins that recognize the cargo proteins, then unfold and translocate them directly across the

lysosomal membrane [160,161]. As my thesis work mainly focused on macro-autophagy, a brief description of this process is given below.

1.4.1 Molecular mechanisms of autophagy regulation

Autophagosome formation requires autophagy related genes called ATGs [162]. The autophagy process is divided into three main steps: initiation, nucleation and expansion (Figure 3).

Initiation requires the unc-51-like kinase 1 (ULK1) complex, which contains ULK1 and ATG13. Induction of autophagy, due to any stress condition or activation signal by signaling molecules, releases the ULK1 complex from mTORC1. ULK1 translocates to the autophagy initiation sites and activates recruitment of a second kinase complex containing VPS34, BECN1, VPS15 and ATG14 [163], which leads to production of PI3P at the autophagosome initiation site. PI3P recruits another protein DFCP1 to start nucleation of autophagosome. The third step requires the ATG16L1-ATG5-ATG12 conjugation machinery for lipidation of light chain 3-II (LC3-II), which initiates the expansion and also fusion between autophagosome and lysosome [164–166].

Two distinct ubiquitin-like protein conjugation systems are involved in autophagy. The first system is ATG5-ATG12 interaction and conjugation, and the second is LC3 processing. The first step involves activation of ATG12 by ATG7 (E1 ubiquitin enzyme) through binding to its C-terminal glycine in an ATP-dependent manner. After that, the ATG12 protein is transferred to ATG10 (an E2 ubiquitin carrier protein) that makes covalent bond of ATG5 to ATG12. The ATG5-ATG12 complex then interacts with ATG16 dimer to form a multimeric ATG5-ATG12-ATG16 complex that fuses with the newly formed extending phagophore. The complex also induces swirl into the growing phagophore through recruitment of processed LC3 [159,167]. The second step is similar to the ubiquitin-mediated protein degradation systems involved in autophagosome. LC3 is present as full-length cytosolic proteins in most cell types. Activation of autophagy, induces proteolytic cleavage of LC3 by ATG4, a cysteine protease to generate LC3B-I. The synthesis and processing of LC3 is increased after induction of autophagy [158]. The activation of the PI3K3 or PI3K is required for formation of autophagosome, which mainly depends on the formation of a multiprotein complex including BECN1 [168].

Figure 3. Different stages of autophagosome and autolysosome formation. Autophagosome formation starts with activation of the ATG/ULK1 complex, which recruits Beclin1 (BECN1) to induce nucleation with VPS34. VPS34 produces phosphatidylinositol-3-phosphate (PI3P), which helps to recruit other ATGs and light chain 3 (LC3). LC3 activation and phosphorylation leads to conjugation with phosphatidylethanolamine (PE). PE acts as a receptor for p62, which binds to ubiquitinated proteins and starts degradation once autophagosome fuses with lysosome and forms autolysosome.

1.4.2 Role of autophagy in tumorigenesis

Autophagy can play a dual role in cancer development. Autophagy genes are commonly deleted in tumors [169,170], leading to increased oxidative stress and DNA damage, which subsequently leads to genomic instability and tumor progression [170–173]. As such, autophagy plays a suppressor role. However, autophagy is induced upon cellular stress such as starvation, oxidative stress and DNA damage [174–177], which protect cancer cells for survival.

13

Autophagy can be suppressed by activation of the PI3K/Akt through activating mutations in PI3K, PTEN loss and AKT amplification, which subsequently leads to activation of mTOR pathway [178,179]. Bcl2 amplification and overexpression inhibit autophagy through BECN1 [180,181]. Nutrient deprivation or genotoxic stress induces p53 expression, which leads to activation of autophagy, due to inhibition of mTOR pathways [182,183]. p53 can suppress autophagy at the basal levels [184]. Ectopic overexpression of p62 inhibits autophagy and leads to tumorigenesis through activation of NF-κB signaling pathway and DNA damage response [170]. Autophagy promotes tumor cell survival under hypoxia or nutrient deprivation [171], as well as type II programmed cell death [185].

1.5   c-KIT IN CANCER

Besmer *et al* first discovered v-KIT in sarcoma virus [186], and one year later, cellular c-KIT was found by Yarden *et al* [187]. c-KIT is a receptor tyrosine kinase (RTK) and a transmembrane protein. It contains an extracellular domain, a transmembrane domain and an intracellular domain (also called kinase domain since most of the phosphorylation sites are present in this domain (Figure 4) [188].

Figure 4. Domain structure of c-KIT. c-KIT is composed of three main domains: (i) The extracellular domain, which consists of five immunoglobulin-like domains, three of them bind to its ligand stem cell factor (SCF), and the fourth is known to help in dimerization; (ii) The transmembrane domain is present in the cell membrane; and (iii) The intracellular domain, which contains the tyrosine kinase domain.

c-KIT is expressed in several cell types such as hematopoietic progenitor cells, germ cells, melanocytes and mast cells. It plays important roles in organogenesis, development, cell differentiation, proliferation, viability and other cellular physiological functions [189–191]. Activation of c-KIT has been observed in several human diseases, including cancer [192–194].

1.5.1 Activation and function

In normal cells, c-KIT is activated after binding of its ligand, called stem cell factor (SCF), to the extracellular domain of c-KIT. SCF induces homodimerization of the intracellular domain or kinase domain of the c-KIT and activates Src-homology2 (SH2), which leads to signal transduction (Figure 5) [190,195]. It can activate several pathways depending on the cellular context, including Ras-MAP kinase, PI3K-Akt-mTOR pathways, Ras-Erk pathways, and PIP3-dependent PKC pathways [196,197]. After activation, c-KIT is then ubiquitinated, which leads to internalization of the receptor and is then transported into lysosomes for degradation [190].

Figure 5. Activation and function of c-KIT. Once stem cell factor (SCF) binds to extracellular ligand binding domain of c-KIT, the dimerization domain is activated and starts dimerization, leading to activation of the kinase domain by phosphorylation. Its signal is then transferred to the nucleus to perform its functions.

c-KIT overexpression has been found in several human cancers, such as gastrointestinal stromal tumor (GIST), mast cell leukemia, testicular germ cell tumors and MCC [188]. Activating mutations of *c-KIT* are frequently observed in human cancers. Till now around 500 different types of *c-KIT* mutations had been reported in human tumors, most of the reported mutations are passenger but some of them are also driver mutations [188]. As an example, in GIST, more than 80% of the tumors contain activating mutations of *c-KIT* [193].

These mutations lead to ligand-independent activation of c-KIT [198–200], which activates PI3K-Akt, STATs and Erk-MAP kinase pathways that promote GIST development [201,202].

1.5.2 Paranuclear c-KIT dot in cancers

As aforementioned, c-KIT is generally expressed on the plasma membrane, where it is activated after binding with its ligand SCF, leading to activation of signaling cascade. However, c-KIT is also present as paranuclear dot-like structure in some cancer types, such as GIST, mast cell leukemia and testicular germ cell tumor [203–205]. For GIST and mast cell leukemia, it is now known that mutations of the *c-KIT* gene contribute to the paranuclear localization [204,206]. However, the exact subcellular localization of paranuclear c-KIT is different between GIST and mast cell leukemia.

In GIST, paranuclear c-KIT is mainly localized on Golgi apparatus [205]. The aberrant kinase activity of mutant c-KIT prevents its transport from the Golgi to the plasma membrane [205] and PKC-Φ promotes stabilization of the mutant c-KIT in the Golgi complex [207]. In mast cell leukemia, c-KIT is mainly localized on endolysosome and endoplasmic reticulum (ER) [204,208,209]. Similar to GIST, the kinase activity of mutant c-KIT is required for the accumulation of mutant c-KIT on endolysosomes via clathrin-mediated endocytosis [210]. Despite their different localizations, they share common oncogenic signaling; mutant c-KIT activates the PI3K-Akt pathway in both cancer types [205,210]. Besides PI3K-Akt pathway, mutant c-KIT can also activate STAT5 and Erk in GIST [205]. On other hand, in mast cell leukemia, mutant c-KIT activates STAT5 on the ER [210].

1.6 ENERGY METABOLISM

Energy metabolism is defined as the process that produces energy for performing all kind of cellular functions in living organisms. There are several processes or pathways in the cells to generate energy including glycolysis, tricarboxylic acid (TCA) cycle, pentose phosphate pathways and mitochondrial respiration. These are the major metabolic pathways in the cells to fulfill their energy requirement and maintain cellular homeostasis.

1.6.1 Glycolysis and mitochondrial metabolism

Glycolysis and mitochondrial energy metabolisms are the most commonly used processes to generate energy in the cells [211,212]. Glycolysis is a process by which glucose molecules are catalyzed by several enzymes and produce, pyruvate, 2 molecules of ATP and NADH each. It is a universal process used by almost all cells [213]. If cells are hypoxic, pyruvate is then converted into lactate [214]. In normal cells, pyruvate is converted into acetyl-coA, which enters the TCA cycles and is further catalysed by a series of enzymatic reactions to produce ATP, NADH and FADH2 as energy intermediates, and releasing CO_2 and H_2O as side products. The FADH2 and NADH produced from the TCA are then transported to the electron transport chain and produce ATP with the help of proton gradient through respiratory complexes I, II, III, and IV [215–218]. Mitochondria also regulate the energy

demand and supply balance by increasing the number of mitochondria whenever they are needed or decreasing the number of mitochondria through fission and mitophagy when the energy demand is less [217,219,220].

1.6.2 Metabolic reprogramming in cancer

Metabolic reprogramming is a hallmark of cancer cells [221]. In general, normal cells mostly rely on mitochondrial oxidative phosphorylation to produce energy to support their activities. However, most cancer cells depend on aerobic glycolysis to generate energy sources to support tumor growth [214,222,223] (Figure 6).

Figure 6. Energy metabolism in normal and tumor cells. Normal cells generally use mitochondrial respiration as a major process to produce energy. In this process glucose is converted into pyruvate by several enzymatic cascades to produce two ATP molecules. The pyruvate is further converted into acetyl-CoA and transported into tricarboxylic acid (TCA) cycle, which produces FADH2 and NADH. These molecules are further reduced in the electron transport chain to produce 32 molecules of ATP. Excessive pyruvate is then converted into lactate, by lactate dehydrogenase enzyme. Unlike normal cells, tumor cells preferentially use aerobic glycolysis and lactate as a major source of energy. This process is also called Warburg effect.

It is now known that several mechanisms can lead to metabolic reprogramming from oxidative phosphorylation to glycolysis in cancer cells. Among them, overexpression of glycolytic enzymes, such as GLUT1, HKII and LDHA, is frequently observed in various cancer cells [224,225]. Lactate dehydrogenases (LDHs) play an important role in the interconversion of pyruvate and lactate. LDHB is responsible for converting lactate to pyruvate that fuels the TCA, while LDHA converts pyruvate to lactate. The balance between

these two enzymatic activities can affect lactate homeostasis in the cells, which can switch between glycolysis and oxidative phosphorylation. Deregulations of these enzymes can lead to metabolic reprogramming, which has been observed in several cancer types, such as pancreatic cancer and lymphoma [226,227]. Additionally, lactate homeostasis also requires monocarboxylic acid transporters (MCTs) that control the excessive levels of lactate in the cells by transporting the lactate across the plasma membrane. High levels of these transporters have also been observed in several tumor types, including breast cancer, choriocarcinoma and head and neck cancer [228–230].

2   AIMS OF THE STUDY

The overall aim of this thesis work was to investigate the functional roles of MCPyV T-antigens in MCC tumorigenesis. The specific aims of the thesis were to:

• Determine the involvement of MCPyV T-antigens in regulation of miRNAs and autophagy (**Paper I**)

• Investigate the expression and function of c-KIT in MCC (**Paper II**)

• Characterize the functional role of *miR-375* and its target LDHB in MCPyV+ and MCPyV- MCC cells (**Paper III**)

• Study the role of MCPyV T-antigens in regulation of LDHB expression and glycolysis (**Paper IV**)

3 MATERIALS AND METHODS

3.1 CELL LINES AND MCC PRIMARY CULTURE

Eight human established cell lines and one primary culture (ME27) were included in this thesis, which are listed in Table 3.

Table 3. Human cell lines and primary culture used in this thesis

Name	Description	MCPyV status	Source	Paper
MCC13	Merkel cell carcinoma	negative	Cell Bank Australia, Westmead, NSW, Australia	I-IV
MCC14/2	Merkel cell carcinoma	negative	Cell Bank Australia, Westmead, NSW, Australia	I-IV
MCC26	Merkel cell carcinoma	negative	Cell Bank Australia, Westmead, NSW, Australia	I-III
WaGa	Merkel cell carcinoma	positive	Gift from Dr. JC Becker (Medical University of Graz, Austria)	I-IV
MKL-1	Merkel cell carcinoma	positive	Gift from Dr. NL Krett (Nortwestern University, IL, USA)	I-IV
MKL-2	Merkel cell carcinoma	positive	Gift from Dr. Roland Houben (University Hospital Würzburg, Germany)	II, III
ME27	Merkel cell carcinoma	positive	Shi et al., unpublished	II
GIST882	Gastrointestinal stromal tumor	n.a.	Gift from Dr. JA Fletcher (Brigham and Women's hospital, Boston, MA)	II
HEK293	Human embryonic kidney	n.a.	Gift from Dr. Yingbo Lin (Karolinska Institutet, Sweden)	II

n.a.=not analyzed

The authenticity of the six MCC cell lines and GIST882 had been confirmed by genotyping of short tandem repeat (STR), as shown in Table 4.

Table 4. Short tandem repeat (STR) profiles of the 6 MCC cell lines and GIST882 used in this thesis

Locus	MCC13	MCC14/2	MCC26	WaGa	MKL-1	MKL-2	GIST882
D8S1179	13, 14	10, 14	8, 10	10, 13	10, 10	11, 13	12, 12
D21S11	30, 31	29, 32.2	31, 32.2	28, 30	30, 30	31.2, 31.2	29, 31.2
D7S820	10, 10	8, 10	8, 9	10, 10	8, 11	10, 13	10, 15
CSF1PO	12, 12	10, 11	10, 11	12, 12	11, 12	10, 12	11, 11
D3S1358	16, 18	16, 16	17, 17	14, 14	16, 16	17, 17	15, 15
THO1	7, 9.3	6, 9.3	9.3, 9.3	9.3, 9.3	9, 9.3	7, 8	9, 9
D13S317	12, 12	13, 13	13, 14	8, 13	8, 11	12, 13	12, 12
D16S539	9, 11	13, 13	11, 13	11, 12	10, 12	10, 12	11, 11
D2S1338	19, 20	19, 19	23, 26	20, 23	17, 17	17, 23	18, 26
D19S433	15, 15	12, 14	16, 16	14, 16	14.2, 15.2	13.2, 14	13, 15
vWA	17, 17	17, 18	16, 18	16, 17	16, 18	16, 17	16, 17
TPOX	8, 8	8, 8	8, 8	8, 11	8, 8	8, 11	11, 11
D18S51	16, 17	15, 17	15, 18	10, 13	12, 18	14, 17	14, 14
AMEL	X, X	X, X	X, X	X, Y	X, Y	X, Y	X, Y
D5S818	9, 12	13, 13	12, 12	12, 12	11, 12	12, 14	12, 12
FGA	19, 20	21, 21	24, 25	19, 19	21, 25	19, 26	23, 23

3.2 MCC TUMOR SAMPLES

Forty-five formalin-fixed paraffin-embedded and 28 frozen MCC tumor samples were collected at Karolinska University Hospital or Stockholm South General Hospital. The diagnosis of MCC was established at the time of diagnosis by routine histopathological and immunohistochemical analyses. Forty-five FFPE samples were used in **Paper I**, 45 FFPE sections in **Paper II** and 28 frozen and 26 FFPE samples were used in **Paper III**. The clinical information of the patients is described in their respective studies.

3.3 RNA EXTRACTION AND RT-QPCR

3.3.1 RNA extraction

Total RNA was isolated by using mirVana miRNA isolation kit (Ambion/Thermo Fisher Scientific, Waltham, MA) and the concentrations were measured with a NanoDrop spectrophotometer (NanoDrop technologies, Wilmington, DE).

3.3.2 Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

RT-qPCR is a reliable method used to detect and measure transcripts in a particular sample through PCR. There are two types of RT-qPCR methods: SYBR green and TaqMan assays. SYBR green is a relative cost effective and easy method to quantify target gene expression. It contains fluorescent dye that binds to dsDNA molecules. The amount of fluorescence measured at the end of each PCR cycle reflects the quantity of the amplified cDNA. This method was used to quantify mRNA expression of MCPyV T-antigens (**Paper I**).

The TaqMan assay requires specific primers and TaqMan probes. TaqMan probe is a sequence-specific DNA molecule with a fluorophore attached at the 5′-end and a quencher at the 3′-end. When the fluorophore and quencher are in close proximity it inhibits the fluorescence signal. During PCR amplification, the *Taq* DNA polymerase extends the primer and cleaves the TaqMan probe through its 5′-to 3′exonuclease activity. After cleaving the probe, the fluorophore is released from the quencher emitting a fluorescence signal for detection and quantification. This method was performed to detect *miR-375*, *miR-30a-3p*, *miR-30a-5p, miR-125a-3p*, *miR-16*, *pri-miR-375*, *pri-miR-30a*, *18S* rRNA and *RNU6B* in **Paper I**, *miR-375*, *LDHB*, *RNU6B* and *GAPDH* in **Paper III**, and *LDHB* and *β-actin* in **Paper IV**. All TaqMan assays were purchased from Applied Biosystems/Thermo Fisher Scientific (Foster City, CA).

3.4 PLASMIDS

Plasmid is a small circular dsDNA molecule that has the capacity to replicate independently from chromosomal DNA. It is widely used as a vector to transfer, multiply or express specific

gene(s) of interest. In this thesis, different plasmids were used to express MCPyV T-antigens, short-hairpin RNA (shRNA) targeting MCPyV T-antigens, miRNAs, miRNA sponges, cellular protein-coding genes and reporters.

3.4.1 MCPyV T-antigens expression plasmids

Five different MCPyV T-antigens expression vectors were used (Figure 7). LTco and sTco are codon-optimized vectors with deleted splicing donor and acceptor sites in the sequence, therefore they only express LT or sT, respectively. LT339 contains tumor-derived LT cDNA isolated from a MCC tumor, which encodes a truncated LT with 469 aa. Additionally, two LT mutants were also applied. $LTco^{D44N}$ expresses a full-length LT with a substitution mutation at residue 44 (D>N) in the HSC70 binding domain, which abolishes the interaction between HSC70 and LT. $LT339_{W209A}$ encodes a truncated LT with substitution of tryptophan for alanine at residue 209, disrupting the interaction between LT and VAM6P.

Figure 7. Plasmids expressing different MCPyV T-antigens and short-hairpin RNAs targeting T-antigens. LTco and LT339 express wild-type and truncated LT, respectively. sTco expresses only small T. $LTco^{D44N}$ has a substitution mutation of aspartic acid at residue 44 with asparagine, while the $LT339_{W209A}$ has alanine substituted for tryptophan at residue 209. shTA is a short hairpin RNA targeting the common exon 1 of both LT and sT, and shsTA only targets the unique region of sT.

3.4.2 Cellular protein-coding plasmids

In **Paper II**, pcDNA3-KIT-WT expressing full-length coding sequence of *c-KIT* was kindly provided by Dr. Lars Rönnstrand (Lund University), and in **Paper IV**, LDHB-FLAG plasmid expressing full-length coding sequence of LDHB and DYKDDDDK(FLAG)-tagged on its carboxyl terminus was purchased from GenScript (Piscataway, NJ).

3.4.3 Short hairpin RNA (shRNA), miRNA expression and sponges

shRNA vector is used to express a single-stranded RNA molecule with a hairpin structure, which can be used to silence a particular target gene by RNA interference (RNAi). Generally, shRNAs targeting specific genes of interest consist of sense and antisense sequences separated by a loop sequence, which folds back into a loop structure after being transcribed. This hairpin transcript is then exported to the cytoplasm and processed by DICER enzyme into ~21-nucleotide small interfering RNA (siRNA) duplexes that are loaded into RISC for gene silencing. In this thesis, shRNAs targeting MCPyV LT and/or sT were performed using shTA and shsTA, respectively (**Papers I** and **IV**). In **Paper II**, two shRNAs targeting common exon 1 of MCPyV T-antigens were used: shTA1 and shTA2. shTA2 targets the 5'UTR of LT/sT at nucleotide 173-193, while shTA1 (same as shTA in **Papers I** and **IV**) targets the nucleotide sequence 222-242 encoding the DnaJ domain of T-antigens (Figure 7). In **Paper II**, shRNA targeting exon 7 of *KIT* was also constructed to silence c-KIT expression.

miRNA expression vectors are similar to shRNAs, which express RNA transcripts with a loop structure. There are two ways to construct miRNA expression vectors. One way is to clone a specific mature miRNA sequence together with its respective complementary sequence and the loop sequence into a vector. Another way is to amplify or synthesize the precursor sequence of specific miRNA (that is known to have a natural hairpin structure after being transcribed) and clone it into a vector. Examples of these designs are illustrated in Supporting Information, Fig. S2 of **Paper I**.

miRNAs sponge vectors express RNA transcripts that contain multiple miRNA binding sites, which can sequester miRNAs from their endogenous targets, thereby inhibiting miRNA function. Description of miRNA sponge vectors for miR-375sp, miR-30a-3psp and miR-30a-5psp is given in Supporting Information, Fig. S1 of **Paper I**.

3.4.4 Reporter constructs

Two types of reporter constructs, mRFP-GFP-LC3 and luciferase reporters, were used in **Paper I**. The mRFP-GFP-LC3 reporter plasmid was used to detect autophagic flux. It is based on the concept of acidic lysosomal pH that quenches the GFP signal in autophagic substrate, which allows us to distinguish autolysosomes and autophagosomes. Autophagosomes are represented by yellow puncta (RFP+/GFP+), and autolysosomes are shown in red puncta (RFP+/GFP-). If both yellow and red puncta are increased, it indicates an increase of autophagic flux. If only yellow puncta are increased, it indicates that autophagic degradation is blocked.

Luciferase is a bioluminescence-producing enzyme commonly found in fireflies. This enzyme can react with a luminescent substrate, luciferin, to produce light emission. There are two commonly used luciferases: firefly and *Renilla* that generate light in the range of 550-570 nm and 480 nm, respectively. Typically, a luciferase gene is cloned upstream or downstream of a specific DNA sequence of interest that allows us to quantify the activity of the target

sequence by measuring the released light. In **Paper I**, luciferase reporters were used to verify specific miRNA binding sites and to determine the efficiency of miRNA sponges.

3.5 TRANSFECTION

Transfection is the most widely used method to introduce external DNA or RNA into the eukaryotic cells. This method is mainly based on opening the pores into the membrane by different mechanisms and delivers the external nucleic acid into the cells. In this thesis lipid based transfection and nucleofection were used.

3.5.1 Lipid-based transfection

Lipid based transfection is based on different charges between the lipid-based reagent and the nucleic acid. The positively charged head group of lipid reagents forms a complex with the negatively charged nucleic acid called liposome. The liposome then fuses with the cell membrane and delivers the nucleic acid into the cells by endocytosis. In this thesis Lipofectamine 2000 was used for transfection of plasmid DNAs and/or siRNAs (**Papers I-IV**). RNAiMAX was used to deliver miRNA mimics into the cells (**Paper III**). miRNA mimics are small chemically modified dsRNA molecules that mimic endogenous mature miRNAs. This transfection method was used for all, except MCPyV+, cell lines.

3.5.2 Nucleofection

For all MCPyV+ cell lines (**Papers I-IV**), nucleofection was used. This method is based on electroporation, which uses a combination of cell-type specific solutions and specific voltage parameters to deliver nucleic acid directly into the nucleus of the cells. This method is suitable for primary cell cultures, non-dividing cells and cell lines that have been difficult to transfect by lipid-based methods.

3.6 PROTEIN EXPRESSION AND MODIFICATION ANALYSES

3.6.1 Western blot

Western blot, also called immunoblot, is the most commonly used molecular biology technique to detect, quantify and identify specific proteins based on their respective molecular weight using a specific antibody. The first step of this method is to extract protein lysates from cells or tissue samples using lysis buffer. Subsequently the protein lysate is loaded onto an electrophoresis gel to separate proteins based on their respective sizes. The proteins are then transferred to a nitrocellulose or polyvinylidene fluoride membrane, and incubated with specific antibodies to the target proteins. After that, washing buffer is used to remove unbound or non-specific primary antibodies from the membrane, followed by incubation with species-specific horseradish peroxidase (HRP) or fluorescent-conjugated

secondary antibody. The results can be detected by chemiluminescence or fluorescence (depending on the type of secondary antibody) using an imaging system.

Besides detection and quantification of specific proteins, Western blot can also be used to detect protein modifications. Protein modification or posttranslational modification of proteins may occur after protein synthesis. There are several types of modification, mostly performed by catalytic enzymes that recognize a specific target sequence or amino acid of the specific proteins. The most common modifications are phosphorylation, acetylation, methylation and glycosylation. In **Paper II**, phosphorylation and glycosylation of c-KIT were analyzed. Protein phosphorylation is a post-translational modification of proteins where a phosphate is covalently bound to an amino acid residue by a protein kinase. Glycosylation is the modification where a carbohydrate is added to a protein. To detect the phosphorylation state of c-KIT, a phospho-specific antibody was used to recognize the phosphorylated amino acid. To assess the glycosylation status of c-KIT, two glycosidases (endonuclease H and peptide:N-glycosidase F) were used to digest high mannose or complex glycan structures, followed by detection of deglycosylated c-KIT using Western blotting.

3.6.2 Immunohistochemistry

Immunohistochemistry is widely used to identify expression levels, tissue distribution and subcellular localization of specific proteins on tissue sections. This method also requires specific antibody to recognize specific antigen in tissue samples, followed by detection of the antibody-antigen interaction using a secondary antibody conjugated with an enzyme or a fluorophore. This method has been applied to detect MCPyV LT, p62 and ATG7 in **Paper I**, and c-KIT in **Paper II**.

3.7   PROTEIN-PROTEIN INTERACTION

Protein-protein interactions play an important role in predicting the functions of specific target proteins. These interactions control a range of biological functions such as metabolic processes, cell-to-cell interactions and development. Around 80% of the proteins work in a group or cluster to perform their functions. There are several methods to identify these interactions. Two of them were used in this thesis, as described below:

3.7.1 Co-immunoprecipitation

Co-immunoprecipitation (co-IP) is a very popular technique to capture the primary target (i.e. antigen) and other proteins that are bound to the target in a protein lysate. Typically, the target protein and its associated protein complex are pulled down using immobilized antibody on beads. The isolated protein complexes are then separated and detected by Western blotting. Besides co-IP, co-localization of two proteins can also be assessed using immunofluorescence microscopy, as described below.

3.7.2 Immunofluorescence confocal microscopy

Immunofluorescence (IF) microscopy is a robust and reliable technique to assess expression and subcellular localization of a target protein. This technique can be used on cultured cells, single cell, and tissue sections. In **Paper II**, IF was used to detect the expression and subcellular localization of c-KIT. In addition, the interaction between c-KIT and BECN1 was also analyzed by co-localization of the two proteins using IF and confocal microscopy.

3.8 AUTOPHAGY ASSAYS

Autophagy is a dynamic process and multiple assays are recommended to verify an autophagic response. In this thesis, three different methods were applied to study the effect on autophagy.

3.8.1 Western blot detection of LC3-II

The LC3 protein is known to be present in all autophagic membranes from an early stage (i.e. phagophore) to a late stage (i.e. autolysosome). The total amount of LC3 is a good indicator of the autophagy index. Full-length LC3 is first cleaved by the ATG4 autophagy protein forming the cytoplasmic LC3-I. LC3-I is then conjugated with phosphatidylethanolamine by ATG7 and ATG3 to form LC3-II. Progression of autophagy can be detected by LC3-I to LC3-II conversion. Detection of LC3-II expression levels at a specific time point is not sufficient to estimate the actual autophagy flux because of its dynamic nature. Increased LC3-II expression levels can either reflect induction of autophagy or inhibition of autolysosme formation. To detect actual induction or inhibition of LC3-II levels, autolysosome formation can be blocked by specific chemical. In this thesis bafilomycin A was used to block autolysosome formation and then detection of the LC3-II level was evaluated with and without the treatment.

3.8.2 mRFP-GFP-LC3 reporter

Another method to evaluate autophagy flux is to measure the LC3 puncta from the mRFP-GFP-LC3 reporter by using confocal microscopy. These puncta correspond to the number of autophagosomes or autolysosomes (refer to Chapter 3.3.4). The principle of this reporter and the interpretation of the fluorescent puncta had been described in Chapter 3.3.4.

3.8.3 Transmission electron microscopy (TEM)

TEM is a powerful technique to study the ultrastructure of cells based on the image generated from a high-energy beam that passes through a very thin tissue section. This method is an important tool to identify autophagic vesicles in cells; however it may not be readily quantifiable. The LC3 immunoblot and reporter assays are more quantitative approaches for monitoring autophagy.

3.9 CELL VIABILITY OR GROWTH ASSAYS

Trypan blue exclusion and WST-1 assays were used to assess cell viability or cell growth in this thesis. These assays are briefly described in the following sections:

3.9.1 Trypan blue exclusion assay

The trypan blue assay is based on the principle that live cells possess a rigid and intact plasma membrane that prevents entry of trypan blue dye, whereas dead cells are not able to prevent the entry of the trypan blue dye. Dead and live cells can be distinguished and quantified using a bright field microscope or an automatic cell counter. This method was used to measure the number of live and dead cells after treatment with bafilomycin A1, torin-1, pan-caspase inhibitor (z-VAD-FMK) or camptothecin (**Paper I**). This assay was also used to assess the effect of *miR-375* and LDHB regulation on cell growth in MCC cell lines (**Paper III**).

3.9.2 WST-1 assay

WST-1 is a colorimetric based assay used for quantification of cell proliferation and viability. The principle of this assay is based on the conversion of tetrazolium salt WST-1 into a colored compound by dehydrogenase enzymes, which are produced by mitochondria. The amount of colored product in the medium is directly proportional to the amount of enzymes produced by the mitochondria; as a result it corresponds to the number of metabolic active cells. This method was used as the primary method for assessment of cell growth or viability in **Papers I-IV**.

3.10 APOPTOSIS ASSAYS

Apoptosis is a form of cell death, which plays an essential role to maintain homeostasis and in the development of organisms. Apoptosis can be induced by several external and internal factors like UV-radiation, DNA damaging chemicals or any kind of stress inside the cells. Apoptotic cells generally display morphological changes (e.g. membrane blebbing, nuclear fragmentation and chromatin condensation) and biochemical modifications (e.g. protein cleavage, DNA breakage). These features are used in the following methods to detect apoptosis.

3.10.1 Annexin V assay

Annexin V has a strong affinity binding specifically to phosphatidylserine (PS). When apoptosis is activated, changes occur in the membrane structure of the apoptotic cells causing PS flips from the inner to the outer membrane surface. This allows the binding of Annexin V to PS of the apoptotic cells. Typically, Annexin V is conjugated with a fluorophore that allows the detection using flow cytometry. Propidium iodide (PI) staining is also commonly used together with the annexin V detection. This stain does not stain viable cells or early apoptotic cells because of an intact plasma membrane, thus enables to distinguish late apoptotic cells from early apoptotic cells. This method was applied in **Papers I**, **III** and **IV**.

3.10.2 Cleaved PARP

Poly (ADP-ribose) polymerase-1 (PARP-1) is a nuclear protein physiologically involved in DNA repair mechanism by adding poly (ADP ribose) polymers in response to several types of cellular stresses. During apoptosis, the full-length PARP-1 (116 kDa) is cleaved by caspases to generate two fragments: 89 kDa and 24 kDa. The 89 kDa carboxyl-terminal fragments containing the catalytic domain has reduced DNA binding capacity and is released to the cytosol, while the 24 kDa fragment irreversibly binds to nicked DNA and inhibits DNA repair. These PARP-1 cleavage products can be detected by Western blotting using specific antibodies targeting these fragments, which had been applied in **Papers II** and **III**.

3.11 METABOLIC ASSAYS

Energy metabolism is the process of energy production from nutrients, which is required to maintain cellular homeostasis in the presence or absence of oxygen. Generally, normal cells rely primarily on mitochondrial respiration to generate energy and cancer cells preferentially use glycolysis. In this thesis, two metabolic assays were used to measure extracellular oxygen consumption and acid production, which monitor rates of glycolysis and respiration (**Paper IV**).

3.11.1 Extracellular Acidification Rate (ECAR)

Glycolysis is a catabolic metabolic process, which provides energy to the cells to maintain their growth, viability and perform all other functions for their survival. In glycolysis, glucose is converted to lactate and protons. As lactate is the source for glycolytic acidification, glycolytic activities can be measured by calculating the rates of extracellular acidification. This assay is based on the pH-sensitive reagent. This reagent is chemically stable and inert. When acidification is increased, it increases the signal for detection.

3.11.2 Oxygen Consumption Rate (OCR)

The second major pathway for cells to provide energy is oxidative phosphorylation. Oxidative phosphorylation uses tricarboxylic acid cycle (TCA), which requires the electron transport chain in the mitochondria using oxygen as a terminal electron acceptor. The Abcam extracellular oxygen consumption reagent is an oxygen-sensitive fluorescent dye, which measures the amount of oxygen in the assay medium. Normally, the dye is quenched by oxygen. During mitochondrial respiration, oxygen is depleted, which reduces the quenching of the fluorescent dye that leads to an increase of the fluorescence signal.

3.12 STATISTICAL ANALYSES

Student's paired t-test was used to compare two groups in transfection experiments (**Papers I-IV**). Multiple comparisons were evaluated using One-way ANOVA with post-hoc Tukey

test (**Paper I**) or Dunnett's test (**Paper II**). Associations of immunohistochemical staining and MCPyV status were assessed using Fisher's exact text (**Paper I**), while correlation between *miR-375* and *LDHB* expressions was evaluated using Spearman's rank order correlation (**Paper III**). All analyses were two-tailed and *p*-values <0.05 were considered as significant.

4 RESULTS AND DISCUSSIONS

4.1 INVOLVEMENT OF MCPYV T-ANTIGENS IN MIRNAS AND AUTOPHAGY REGULATION (PAPER I)

In our previous study, we identified a subset of miRNAs associated with MCPyV status in MCC clinical samples [150]. Two of these MCPyV-associated miRNAs (*miR-375* and *miR-30a-5p*) are known to target autophagy genes [231–233]. We therefore investigated whether MCPyV T-antigens could regulate these specific miRNAs and autophagy.

4.1.1 MCPyV T-antigens regulate miRNAs through the DnaJ domain of T-antigen

We first determined whether MCPyV T-antigens could regulate specific miRNA expression. Here, we had chosen to analyse three MCPyV-associated miRNAs, i.e. *miR-375*, *miR-30a-3p* and *miR-30a-5p*, identified from our previous study. Indeed, silencing of MCPyV LT and/or sT in MCPyV+ MCC cell lines decreased levels of *miR-375*, *miR-30a-3p* and *miR-30a-5p*. Concordantly, ectopic expression of MCPyV sT, full-length or truncated LT in MCPyV- MCC cell lines increased the expressions of these miRNAs. To demonstrate the specificity of the results, we also included two non-MCPyV-associated miRNAs (*miR-125a-3p* and *miR-16*), which did not show significant changes upon modulation of MCPyV T-antigen expressions. We further showed that silencing of LT and/or sT had no effect on the primary transcripts of *miR-375* and *miR-30a*, excluding the effect at transcriptional levels. On the other hand, silencing of LT and/or sT reduced the stability of these mature miRNAs, suggesting that the viral T-antigens regulate these miRNAs at post-transcriptional level.

We next sought to identify which domain of the viral T-antigens is required for miRNA regulation. We focused on the DnaJ domain because it is shared between the LT and sT. Here we applied a mutant in the DnaJ domain, D44N, and compared the effect with its wild-type. Our results revealed that the DnaJ mutant completely abolished the LT-induced miRNA expressions. Further investigations are now being performed to address the mechanism how MCPyV T-antigens regulate these miRNAs through the DnaJ domain.

4.1.2 MCPyV-regulated miRNAs targets multiple autophagy genes

miR-375 and *miR-30a-5p* are known to suppress *ATG7* and *BECN1*, respectively [231,232]. Here, we showed that these two miRNAs could also target these autophagy genes and suppress autophagy in MCC cell lines. Additionally, we discovered that *miR-375* could also target the autophagic receptor *SQSTM1* (also known as p62), which binds directly to LC3 to facilitate autophagic degradation. Similarly, we also observed that, besides *miR-30a-5p*, *miR-30a-3p* also regulates BECN1 expression. Using a computational approach, we identified a putative target site in the coding sequence of *SQSTM1* and *BECN1*. Further experiments validated the direct interactions between *miR-375* and *SQSTM1*, as well as between *miR-30a-3p* and *BECN1*, using luciferase reporter assays. *miR-30a-3p* was also verified to regulate autophagy using Western blot analysis of LC3-II and mRFP-GFP-LC3 reporter assays.

4.1.3 MCPyV sT and truncated LT regulate autophagy

Given that these three miRNAs were regulated by MCPyV T-antigens, we investigated whether MCPyV T-antigens could also regulate autophagy. Indeed, our results showed that silencing of MCPyV LT and/or sT in MCPyV+ cell lines increased LC3-II levels in the presence or absence of bafilomycin A1 by Western blotting, as well as the number of autophagosomes and autolysosomes by LC3 fluorescence reporter assay and transmission electron microscopy. Concordantly, ectopic expression of truncated LT and sT could suppress autophagy in MCPyV- MCC cell lines; however the wild-type LT did not have significant effect on autophagy. One plausible explanation for this effect is that the carboxyl-terminal of wild-type LT can induce autophagy by DNA damage response that counteracts the autophagy suppression effect.

To evaluate the clinical significance of our findings, we evaluated immunohistochemical staining of ATG7 and p62 in 45 MCC tumors. Our results revealed that both ATG7 and p62 expressions were lower in MCPyV+ than MCPyV- MCC tumors, suggesting the involvement of MCPyV oncoproteins in regulation of autophagy genes that leads to autophagy suppression. However, the viral oncoproteins can also suppress autophagy through other mechanisms, such as c-KIT in **Paper II**.

4.1.4 Inhibition of autophagy rescues cell death induced by Torin-1

Here, we hypothesized that suppression of autophagy could protect MCC cells from cell death in MCPyV + MCC cells. To address this question, we evaluated the effect on viability in cells treated with Torin-1 (an mTOR inhibitor) or a combination of Torin-1 and bafilomycin A1 (autophagy inhibitor) or z-VAD-FMK (pan-caspase inhibitor). Using WST-1 and Annexin V assays, we showed that inhibition of autophagy could rescue cell death induced by Torin-1, however inhibition of caspases could not rescue cell death. The results suggest that suppression of autophagy is important for MCC cell survival.

In summary, we describe a network that MCPyV oncoproteins and their-regulated miRNAs can hijack the autophagy machinery in MCC by directly targeting multiple autophagy genes. Suppression of autophagy could protect MCC cell survival. Our findings may shed light on a potential therapeutic strategy for this aggressive disease.

4.2 EXPRESSION AND FUNCTION OF C-KIT IN MCPYV+ MCC (PAPER II)

c-KIT is a receptor tyrosine kinase that is commonly overexpressed and activated in cancer [193,234]. Similar to other tumor types, c-KIT overexpression has been reported in MCC and is associated with poor prognosis [235]. However its functional role in MCC is yet to be determined.

4.2.1 MCPyV truncated LT induces paranuclear retention of c-KIT

We first investigated c-KIT expression in both MCPyV+ and MCPyV− MCC cell lines using immunofluorescence. Unexpectedly, we observed paranuclear dot-like staining of c-KIT in all three MCPyV+ MCC cell lines, but its expression was barely detectable in all three MCPyV- MCC cell lines. Similarly, the paranuclear dot-like staining was also more commonly observed in MCPyV+ than MCPyV- MCC tumors; On the other hand, membranous staining of c-KIT was more common in MCPyV- MCC tumors.

We then assessed whether MCPyV T-antigens play a role in paranuclear localization of c-KIT. Indeed, when we silenced MCPyV T-antigens in the MCPyV+ WaGa cells, the number of cells with paranuclear c-KIT dot structure was markedly reduced. On the other hand, we observed an increase number of cells with cytoplasmic distribution of c-KIT. To further evaluate which viral T-antigen(s) contribute to the paranuclear c-KIT dot, we ectopically co-expressed c-KIT and MCPyV sT, wild-type or truncated LT. The results showed that only the truncated LT could recapitulate the paranuclear dot of c-KIT. The LT is known to interact with Vam6p [62], which is involved in lysosome trafficking [236]. We therefore hypothesized that the interaction between LT and Vam6p results in paranuclear retention of c-KIT. Using the W209A mutant of LT339 (which is defective in Vam6p interaction), the paranuclear retention of c-KIT was abolished.

The next question was to address the subcellular localization of c-KIT. Using immunofluorescence, our results showed that the paranuclear c-KIT was partially overlapped with the Golgi marker (GOLGB1). As c-KIT proteins undergo a series of glycosylations, we assessed the glycosylation status of c-KIT in MCPyV+ MCC cells. The results revealed that c-KIT proteins in the MCPyV+ cell lines were mainly in the mature form (145 kDa) and complex glycosylated, as evidenced by digestion with the PNGase F but not with the endo H. Furthermore, we observed that all three MCPyV+ MCC cell lines had detectable level of phospho-KIT, as detected by immunoblotting. These results suggest that the complex glycosylated c-KIT has been transported to the plasma membrane and activated by its ligand, SCF. We therefore hypothesize that the endocytosed c-KIT is likely blocked from degradation by the LT-Vam6p interaction, leading to stabilization of c-KIT in the paranuclear compartment. In line with our hypothesis, using immunoblotting, we observed an accumulation of c-KIT in the truncated LT-expressing cells and very low c-KIT expression in cells expressing sT or full-length LT. Ongoing experiments are conducted to address whether c-KIT is accumulated on the Golgi from the early secretory or endocytic pathways.

4.2.2 c-KIT interacts with BECN1 in MCPyV+ MCC cell lines

In **Paper I**, we have shown that MCPyV truncated LT can inhibit autophagy and another tyrosine kinase receptor, epidermal growth factor (EGFR), has been demonstrated to suppress autophagy through BECN1 [237]. We therefore sought to address if c-KIT also interacts with BECN1 and suppresses autophagy in MCPyV+ MCC. Using co-immunostaining of c-KIT and BECN1, BECN1 and c-KIT were in very close proximity within the paranuclear dot-like

region. To further strengthen the results, the interaction between BECN1 and c-KIT was confirmed by co-immunoprecipitation and reciprocal immunoprecipitation assays.

4.2.3 Silencing of c-KIT induces autophagy and apoptosis in MCPyV+ MCC

To address the involvement of c-KIT in regulation of autophagy, we silenced c-KIT in WaGa cells and evaluated the effect on LC3-II levels with and without bafilomycin A1 treatment using Western blotting. The results showed an induction of LC3-II in the absence or presence of bafilomycin A1. c-KIT can activate AKT-mTOR signaling, which can also suppress autophagy [238]. We therefore examined whether AKT-mTOR signaling contributes to c-KIT-mediated autophagy regulation in MCC. Our results showed that silencing of c-KIT led to subtle decreases in both phosphorylation statuses of mTOR and/or AKT, suggesting that c-KIT-mediated autophagy suppression may partly depend on the AKT-mTOR signaling pathways.

Besides autophagy regulation, we also observed an increase of apoptosis upon silencing of c-KIT, as indicated by increased expression of the 89-kDa cleaved PARP. The increased expression of cleaved PARP was also noted in the c-KIT-depleted cells with inhibition of autophagy, suggesting that the apoptosis was not induced by autophagy. Together, our results demonstrate that c-KIT is required for autophagy suppression and cell viability in MCPyV+ MCC cells.

4.2.4 Autophagy can degrade LT protein

Unexpectedly, we observed reduction of MCPyV LT in the c-KIT-depleted cells and its level was restored upon treatment with the bafilomycin A1 autophagy inhibitor. We therefore evaluated whether MCPyV LT is degraded by autophagy. Indeed, our results showed that LT expression was decreased upon induction of autophagy (by EBSS or Torin-1), and restored upon inhibition of autophagy (by bafilomycin A1). To strengthen the results, we are now silencing autophagy genes and assess the degradation rate of viral oncoproteins.

Collectively we uncovered a novel mechanism where the viral truncated LT can promote paranuclear retention of c-KIT, and a new role for c-KIT in autophagy regulation through interaction with BECN1.

4.3   FUNCTIONAL STUDIES OF *MIR-375* AND LDHB IN MCC (PAPER III)

In **Paper I**, we identified *miR-375* as one of the differentially expressed miRNAs between MCPyV+ and MCPyV- MCC tumors. This miRNA is highly abundant in most MCC tumors and its high levels in serum samples correlate with tumor burden in MCC [151]. *miR-375* has been demonstrated to promote neuroendocrine differentiation in MCPyV- MCC cell lines. However, its functional role in MCPyV+ MCC remains undefined. LDHB, one of the known targets of *miR-375*, has been detected in MCC tumors [239]. In this study, we investigated whether *miR-375* could regulate LDHB and their functional roles in MCC.

4.3.1 *miR-375* regulates LDHB levels in MCC

We first evaluated whether LDHB could be a target of *miR-375* in MCC. In consistent with higher levels of *miR-375* in MCPyV+ than MCPyV- MCC tumors observed in **Paper I**, *miR-375* levels were also higher in all three MCPyV+ MCC cell lines (WaGa, MKL-1 and MKL-2) compared to the three MCPyV- MCC cell lines (MCC13, MCC14/2 and MCC26). On the other hand, LDHB mRNA and protein levels were higher in the MCPyV- than MCPyV+ MCC cell lines. Furthermore, *LDHB* mRNA levels were also inversely correlated with *miR-375* in MCC tumor samples. Additionally, overexpression of *miR-375* in MCPyV- MCC cells reduced, and silencing of *miR-375* induced, LDHB mRNA and protein levels. These results indicate that LDHB is a target of *miR-375* in MCC.

4.3.2 *miR-375* overexpression suppresses cell growth and migration in MCPyV- MCC cell lines

To determine the functional role of *miR-375* in MCC cells, we overexpressed *miR-375* in MCPyV– MCC cells using *miR-375* expression plasmid or mimic and evaluated the effect on functional phenotypes. Our results showed that *miR-375* overexpression reduced cell growth, as assessed by WST-1 and trypan blue exclusion assays. Furthermore, over-expression of *miR-375* led to a subtle increase in G1 or G2 phases compared to the negative control. Using wound healing scratch assay, we observed a reduction in wound closure rate compared to the negative control in *miR-375*-overexpressing cells. In addition, overexpression of *miR-375* increased the expression of cleaved PARP, an apoptotic marker. Together, our results suggest that *miR-375* functions as a tumor suppressor in MCPyV- MCC cell lines, by inhibiting cell growth and migration, as well as inducing apoptosis.

4.3.3 Suppression of *miR-375* decreases cell growth and increases apoptosis in MCPyV+ MCC cell lines

In MCPyV+ MCC cell lines, inhibition of *miR-375*, using miRNA sponges, reduced cell growth in both WaGa and MKL-1 cell lines, as evaluated by trypan blue exclusion and WST-1 assays. Concomitantly, suppression of *miR-375* led to an increase of apoptosis, as evaluated by Annexin V and caspase-3 activity assays. The results indicate that *miR-375* is required for cell growth and viability in MCPyV+ MCC cells.

4.3.4 Silencing of LDHB reduces cell growth in MCPyV- MCC cells but rescues cell growth suppression mediated by *miR-375* inhibition in MCPyV+ MCC cells

We further investigated whether LDHB plays a role in *miR-375*-mediated cell growth in MCPyV+ MCC cell lines. We determined cell growth in cells transfected with miR-375sp together with and without siRNAs targeting LDHB, as well as cells transfected with miR-375sp or vehicles only. Inhibition of *miR-375* reduced cell growth and silencing of LDHB rescued the cell growth inhibition effect caused by *miR-375* suppression. On the other hand, silencing of LDHB decreased cell growth and increased apoptosis in MCPyV- MCC cell lines.

Collectively, our study suggests that LDHB functions as an oncogene in MCPyV- MCC, and a tumor suppressor in MCPyV+ MCC cell lines. Given that LDHB is a key enzyme involved in energy metabolism, we speculated that the differential role of LDHB could relate to different cellular metabolisms in MCPyV+ and MCPyV- cells, which led to the investigations in **Paper IV**.

4.4   MCPYV T-ANTIGENS AND LDHB IN GLYCOLYSIS IN MCC (PAPER IV)

In **Paper III**, we have shown that LDHB can regulate cell growth in MCC cells, and depending on virus status, LDHB can be an oncogene or a tumor suppressor. Given that LDHB is a metabolic enzyme involved in glycolysis and its expression level is associated with the virus status, we investigated whether MCPyV T-antigens could regulate LDHB levels and its effect on energy metabolism and cell growth.

4.4.1 MCPyV T-antigens regulate LDHB expression and glycolysis

Using RT-qPCR and Western blotting, we showed that silencing of MCPyV T-antigens increased LDHB expression at mRNA and protein levels in MCPyV+ MCC cells, while ectopic expression of MCPyV sT and truncated LT decreased LDHB expression in MCPyV- MCC cell lines. Silencing of MCPyV T-antigens also decreased glycolysis rates and ectopic expressions of sT and truncated LT increased glycolysis. Cells expressing wild-type LT did not have consistent effect in MCC13 and MCC14/2 cells; its glycolysis rate was similar to the vector control in MCC13 but increased in MCC14/2 cells. Together, our results showed that MCPyV sT and truncated LT could suppress LDHB expression and promote glycolysis.

4.4.2 LDHB overexpression reduces cell growth and induces apoptosis in MCPyV+ MCC cell lines

In **Paper III**, we demonstrated that silencing of LDHB rescued *miR-375*-mediated cell growth suppression in MCPyV+ MCC cell lines. To demonstrate the direct effect of LDHB as a suppressor in MCPyV+ cells, we ectopically expressed full-length coding sequence of LDHB in WaGa and MKL-1 cell lines. We observed that LDHB overexpression reduced cell growth and increased apoptosis in both cell lines, supporting its tumor suppressor role in MCPyV+ MCC cells.

4.4.3 Ectopic expression of LDHB reverses the growth-promoting effect of MCPyV oncoproteins

We next investigated whether the functional role of LDHB is dependent on MCPyV oncoproteins by comparing the effects of cells co-transfected with MCPyV T-antigen together with and without ectopic LDHB expression in MCPyV- MCC cell lines. Our results showed that sT and LT339 increased cell growth in both cell lines, which is consistent with the results reported in previous studies [15,240]. However, the full-length LT did not have significant effect on cell growth. Co-transfection of LDHB and sT or LT339 reversed the

growth-promoting effect of these viral oncoproteins. Similarly, cells transfected with LDHB and sT or LT339 had more apoptotic cells than the cells transfected with sT or LT339. No differences were observed for cell growth and apoptosis in cells expressing full-length LT with and without ectopic LDHB. These findings suggest that low LDHB level is important for cell growth and viability of viral oncoproteins expressing cells, due to reprogramming of energy metabolism in the cells. Cells expressing viral oncoproteins may rely on glycolysis for promoting cell growth. Increased LDHB expression promotes conversion of lactate to pyruvate for the TCA cycle that switches from glycolysis to oxidative phosphorylation. These observations led us to investigate whether MCPyV+ and MCPyV- MCC cells are dependent on different metabolic activities for cell growth.

4.4.4 MCPyV + and MCPyV- MCC cells rely on different energy metabolism for cell growth

To address this question, we treated MCC cells with oxamic acid (glycolysis inhibitor) or antimycin A (oxidative phosphorylation inhibitor). In MCPyV+ MCC cells, we found that oxamic acid-treated cells reduced glycolysis in both cell lines, while treatment with antimycin A increased glycolysis due to increased lactate production [226]. Inhibition of glycolysis reduced cell growth in MCPyV+ MCC cell lines, while inhibition of oxidative phosphorylation had no effect on cell growth. In MCPyV- MCC cell lines, antimycin A treatment reduced oxygen consumption rate (OCR), while oxamic acid treatment did not have any effect on OCR. Antimycin A treatment inhibited cell growth in MCPyV- cell lines, but not with oxamic acid.

In summary, our findings revealed that MCPyV oncoproteins suppress LDHB expression and induce glycolysis for promoting cell growth and viability in MCC. MCPyV+ and MCPyV- MCC cells are dependent on different energy metabolism for cell growth, which leads us to propose targeting metabolism as an alternative strategy for treating MCC patients.

5   CONCLUSIONS

MCPyV oncoproteins (sT and truncated LT) clearly play important roles in MCC tumorigenesis. This thesis explored the involvement of the viral oncoproteins in regulating miRNA expressions, autophagy and metabolism. The main findings of this thesis are summarized below:

- MCPyV T-antigens regulate a subset of miRNAs, including *miR-375*, *miR-30a-3p* and *miR-30a-5p*, through the DnaJ domain of viral T-antigen (**Paper I**).

- MCPyV oncoproteins can suppress autophagy via multiple mechanisms, including miRNA regulation of multiple autophagy genes and c-KIT interaction with BECN1 (**Papers I and II**).

- *miR-375* can regulate autophagy by targeting *ATG7* and *SQSTM1*, and metabolism by suppressing *LDHB* (**Papers I and III**).

- c-KIT can regulate autophagy and apoptosis in MCPyV+ MCC cells (**Paper II**).

- The Vam6p of MCPyV truncated LT is required for paranuclear retention of c-KIT (**Paper II**).

- *miR-375* and LDHB have different functions in MCC cells with and without MCPyV (**Paper III**).

- Low level of LDHB is required for cell growth and viability in MCPyV+ cells (**Paper IV**).

- MCPyV+ MCC cell lines are dependent on glycolysis and MCPyV- MCC cell lines rely on oxidative phosphorylation for cell growth and viability (**Paper IV**).

6 FUTURE PERSPECTIVE

This thesis work describes new functions of MCPyV T-antigens, *i.e.* autophagy suppression and reprogramming energy metabolism. Mechanistically, the viral oncoproteins could suppress autophagy through miRNA regulations and c-KIT interaction with BECN1. Suppression of autophagy is crucial to sustain MCPyV T-antigen expression and cell viability in MCC (**Papers I** and **II**). On the other hand, MCPyV T-antigens can reprogram energy metabolism through regulation of LDHB expression levels (**Paper IV**) or other glycolytic genes, such as MCT1 [75]. These findings reveal the involvement of autophagy and metabolism reprogramming in MCC tumorigenesis. Further studies investigating the functional impact of autophagy suppression and glycolysis may facilitate our understanding the role of the viral oncoproteins in MCC development.

In **Paper I**, we demonstrated that MCPyV T-antigens could regulate specific miRNAs at post-transcriptional level. Although we identified that the DnaJ domain of the viral T-antigens is crucial for miRNA regulation, the molecular mechanism of this regulation is still unclear. Within the DnaJ domain, there is an Hsc70 binding site. Hsc70 can bind to the AU-rich elements (AREs) of *Bim* mRNA and regulate its mRNA stability [241]. This leads us to hypothesize that the interaction between MCPyV T-antigens and Hsc70 can increase mRNA stability and/or translation of miRNA processing gene(s).

In **Paper II**, we have shown that c-KIT is mainly localized on Golgi apparatus; however it is still unclear whether c-KIT accumulated on the Golgi after the early secretory pathway or endocytosis from the plasma membrane. Although we showed that c-KIT interacts with BECN1, the interaction sites between c-KIT and BECN1 and the mechanism of this interaction that contributes to autophagy suppression remain to be determined.

In **Papers III and IV**, we demonstrated that MCPyV oncoproteins could regulate LDHB expressions and glycolysis; it is still unclear how these viral oncoproteins regulate LDHB expression, which leads to change of the energy metabolisms in MCCs.

Although recent studies revealed a positive outcome with anti-PD-1 or anti-PD-L1 treatment in advanced MCC patients, the long-term outcomes of these patients remain unknown; moreover, half of them are still refractory to these immune-checkpoint inhibitors. Identification of alternative treatment options for advanced MCC patients are still warranted. Delineating the functional roles of MCPyV oncoproteins in MCC may lead to identification of new avenues for developing novel therapeutic approaches for MCC treatment.

7 ACKNOWLEDGEMENTS

I am very fortunate to meet and get to know so many people during my PhD in the last five years, not only in Karolinska Institute, but also outside of Karolinska. Whenever I will look back on my PhD journey, I will always think about all of you with a smile and wish to go back to that journey again and again. Thanks to all of you for sharing that priceless time with me during this journey.

This journey was both very exciting and challenging for me. It was very hard in the beginning, but once I got to know about the working environment, it became easier to continue. Many people around me gave me their valuable time, guidance and support in many different ways. Without support or help of all of you, this PhD journey would not have been possible. Here I will express my deepest and heartfelt gratitude to all of you.

I owe sincere and heartfelt gratitude to my main supervisor, **Weng-Onn Lui** for accepting me as a PhD student in your small RNA research group. You gave me immense support from the very first day, when I landed in Stockholm and you came to pick me up from Arlanda airport till my last day when I was struggling to write my thesis. I always admired your knowledge and enthusiasm to explore scientific questions, critical thinking - not only in the RNA field, but also every other field of life science, your passion for scientific research and also getting new ideas. I want to thank you for guiding me and giving me advise at every step of my whole PhD journey to make me a better scientist; so that I can think of new hypothesis and design all the experiments myself. Thanks for patiently helping me to correct and finalize all my manuscripts and this thesis till the last minute of my PhD. You taught me how to write manuscripts and abstracts and how to present my research briefly. I am very fortunate to have you as my main supervisor. I will cherish these five years for my whole life and look back and try to learn from it.

Thanks to **Catharina Larsson**, my co-supervisor who has been a great inspiration for me during my PhD. I learnt from you to smile all the time, no matter if I am stressed or in any kind of trouble. I always observed you during our meetings and tried to learn how to find solutions for any kind of problem either for manuscripts or for problems outside of science. After every meeting you always said that the results look good, that everything will be fine and these words always give me the courage and motivation to work hard and get good results. I learn a lot from you during my PhD journey; it will help me to build my future.

My co-supervisor **Hong Xie,** you supported and helped me a lot during the start of my PhD. You first introduced me to the Merkel cell carcinoma project and provided me with all the information regarding Merkel cell carcinoma cell culture, and nucleofection. You guided me to clone all the required vectors, which I used for my PhD project. You are a bundle of energy, who never gets tired of research work. Thank you for your answers to all my stupid questions and your time helping me to solve my all my problems regarding experiments. Thanks for replying to my entire message no matter if early morning or late night. Whenever

I need any data from you, you are ready to send it to me immediately or tell me you will send as soon as possible. I will always remember the advice and guidance you provided during my PhD studies. I wish you could have stayed here during my whole PhD - it would have been nice for my development, but still I am really lucky that I got the chance to work with you.

Viveca Björnhagen, I admire you because being a very busy surgeon you still always found the time to attend the meeting and give us a lot of clinical information about MCC. You are a nice collaborator and without your help by providing us with MCC tumor samples my PhD would not have been possible. Whenever I called for a signature, you were always available and after signing the documents you gave me encouragement and told me everything will be fine with a nice smile. I will always remember your help and support. Thank you for being my co-supervisor.

Anders Höög, I am really lucky to have you as my co-supervisor. Thanks for providing all pathological information about the MCC tissue samples. I learned a lot from you about MCC diagnosis and detection. Whenever we had meetings, you always provided a lot of information. I admire you, because you are always up to date with new techniques or antibodies used for detection of MCC. I will always remember your sentence: Submission of a manuscript is silver, but acceptance is gold and you will get the gold soon. Thanks for your help during my PhD study.

I would like to thank **Drs. N.L. Krett** and **J.C. Becker** for providing MCC cell lines, **Dr. James A. DeCaprio** for providing the Ab3 antibody; **Drs P. Moore** and **Y.Chang** for providing the antibody and plasmids, **Drs J. Füllgrabe** and **B. Joseph** for giving valuable suggestions and reagents related to autophagy experiments, **Dr K. Hultenby** for the advice and help in electron microscopy, **Dr. Ronald Houben** for providing MCC cell lines and **Ms L. Ånfalk** for processing tumor specimens. I will always remember your help and contribution, which made my PhD thesis work possible.

I would like to give special thanks to Professor **Stefan Schwartz,** who agreed to be opponent for my PhD thesis defence; Associate Professor **Gerald Mcinerney** and Associate Professor **Tanel Punga** for agreeing to be members of the examination board; also thanks to Associate Professor **Gerald Mclnerny** and Associate Professor **Mikael Lindström** as the member of my half-time control. I really appreciate your valuable suggestions and enjoyed the discussion during my half-time. I would like to give special thanks to Associate Professor **Ning Xu** for being coordinator of my PhD examination board and half-time control. I really appreciate your suggestions during half-time control, it was very useful and helps me to make my manuscript better; special thanks to my mentor **Angelo**, thank you for being my mentor and giving me valuable tips for autophagy detection and providing information about new technique.

Present and past member in Catharina Larsson´s lab:

Ninni Mu, there are no words to describe your contribution to boost my morale. Whenever you see me working or thinking, you always say do not worry, everything will be fine. You are the best in statistics and clinical knowledge. Thank you for the fun we had during our Gotland trip and ski trip, I will cherish that forever and for your laughter and motivation, which makes the lab work easier and more fun; **Yaxuan Liu,** a smart and kind-hearted girl and my lunch partner. Thank you for waiting and asking me for lunch every day. I always think that you have perfect timing and the perfect response to shut people up, when they try to make fun of you. I will remember our ski trip in Stockholm and Alpine and the time we spent for badminton, it was really fun; **Omid Fotouhi,** I am glad to have you as my lab colleague. It was always nice to have discussions about current work and future work as well as personal life. Thank you for organizing the book club, it helped to regain my knowledge about cancer and molecular mechanism of cancer development; **Na Wang,** I admire your time management skill, how you manage time between your work and personal life – it is really amazing. You always come to the lab in a hurry and finish your work soon and go back to take care of your kids, it's unbelievable. Thank you for sharing your knowledge and life experience and also amazing food; **Fredrika,** I am amazed how you manage your clinical work and research together. I heard one of your secrets: you love steak. I hope we can all go to eat steak one day; **Johan**, I heard you want to learn Chinese very eagerly. I hope you can succeed to learn as soon as possible. I wish you good luck for your research work; **Jikai**, an exchange student from China and my first badminton coach. Thank you for teaching me badminton and sharing lunch after badminton. You should also try other food than Chinese; **Tilak,** a smart and intelligent high school student that came for an internship and surprised us with his knowledge. I wish you good luck for your graduation. I hope you will succeed in the medicine field.

Special thanks to **Svetlana Langercrantz,** Thanks for inviting me for dinner at your home during my first summer in Stockholm. It was amazing to experience Swedish culture and the songs you sing at different occasions; **Christofer Julin,** a smart and handsome pathologist. I always wondered how you manage with your very busy schedule to go to gym to maintain your fitness. Thank you for your help to score the ATG7 and p62 slides - without your help it would have been very difficult to quantify them; **Pedram**, the superman of the Catharina Larsson´s group. I wish one day I will succeed to perform all the experiments faster than and as successful as you. Thank you for help and important advice during these days.

Thanks to the friends in CCK, who made my PhD journey enjoyable:

Soniya Ma´am, thank you for taking care of me from my first day till now as my guardian. Thank you for sharing your situations, personal problems and also roaming around together in the city - it made my stay in Stockholm easier; **Min Guo,** although you are not in the small RNA group, I always considered you part of the group. You are one of my closest friends or rumored girlfriend. Thank you for discussing everything with me. We had a lot of fun during these four years, you are the first friend I made in Stockholm and we are still best friends. It

was fun to listen to the gossip about us. Once I overheard, I told you and and we laughed. We also went for a conference together and also several trips in Sweden, it was wonderful to spend time with you and enjoy our trips and roam around in the city to find delicious food. It was amazing to go to Swedish class with you, without you, I could never have learned even a single word of Swedish. We always enjoyed MacD burger and chilli cheese during lunch breaks of our Swedish course. Thank you for being both nice and mean to me at the same time. Soon I will find a nice apartment for you, so I can rent from you when I am homeless and also after my defence I will have time to find a handsome guy for you; **Ishani**, thank you for helping me during my research work. I really appreciate your help providing information regarding VISA or travel grants. It was an amazing experience to visit Disney land and Universal studio with you guys; **Arvindh**, thank you for helping me during the application process and giving tips for thesis writing; **Chen,** funny and badminton lover guy. One day I will play badminton tournament against you and win for sure after my defence; thanks for sharing your knowledge, teaching me FACS (Novocyte) and for the fun time during my PhD study; **Christos Coucoravas,** always making everyone laugh during the lunch break. It was amazing to talk with you regarding work and life. Thank you for motivating me, saying do not worry Satendra, you will be alright. **Ying, Neo** and **Kristina**, I get to know you guys as well after moving to Bioclinicum, during that short time we became such nice friends it feels like we know each other from a long time. Thank you for having lunch and late night dinner together.

I would also like to thank many other wonderful friends in CCK**, Emma, Sophia, Miria my KI lopet running partner, Angelos**, **Muyi**, **Ali Reza, Yi, Chen, Yingbo Lin, Yuan Ma** for the memorable and fun times in CCK.

Thanks you all the people of the Onco-Pat, especially Erika, Soren, Hannah, Elisabeth and Eva, for your priceless supports and work to run the CCK administration and shop smoothly.

Friends Outside of CCK and work in Stockholm

My closet friends and apartment mate **Kunal**, thank you for being always nice and supportive. I have enjoyed cooking breakfast, lunch and dinner together and watching Cricket, football and badminton during weekends or week days; without you it would not have been so much fun to cook or watch sports. Thank you for giving me good advice about research and personal life, it helped me a lot during these days. It was a lot of fun to discuss the cricket match after winning or losing our game. Our friendship will last forever. I wish you all the best for your PhD, it will be amazing, I have no doubt about it. **Ankit,** I remember the first time, when we meet near the KI library during Cricket practice, from that day till now our friendship became deeper and deeper; I always enjoyed and learn from you during badminton. Thanks for helping me during my half-time and also during the application process, you always offer to help with anything. **Monica** thanks for being a nice friend and inviting me for dinner. I admire your courage to switch the field from research to IT. I wish you good luck for your future and I am sure you will be successful as an ITian as well. **Anuj Sir**, Thank you for all the good advice from the start of my PhD till now. **Shahul,** I am

always wondering, how much truth is in your weekend stories about girls. We will definitely find out one day. Thanks for your advice and being my badminton partner during the tournament.

I would like to thank all my friends from the Cricket group, **Sachin, Nilesh, Madhurendra, Harkamal, Kalai, Sampath, Pradeep, Sulaiman, Akram, Vivek Lanka, Vivek Sharma, Deepak, Suhas**, and others thank you for being good friends not only on the Cricket ground but also outside. You guys made my PhD journey memorable. I will always remember the time we spent together during dinner or get together, you guys made me forget that I am living outside of India. I never felt homesick, only because you guys were always there to cheer me up in every situation. I cannot describe the amount of love and respect I got for you guys.

I would like to thank all my friends, I made over the years in Stockholm, thanks to the Cricket community and Captain **Nilesh**, I made a lot of wonderful not just friends but family outside of India, **Sneha, Neha, Daya, Ankur, Sachin Thankre, Swapnali, Monali, Ashwini, Suvarna, Aarush, Rushabh, Abhay, Himanshu, Ganesh, Gayatri, Prajakta, Manika, Pallavi and Saranya,** I will never forget our get together to celebrate birthdays or festivals or find any excuse to meet and enjoy our time. It was really fun to have you guys here as my close friends. Special thanks to our **proudly half dead** group members, you guys make this journey more memorable with our regular dinner at rotation policy although I always escape to invite at my place, but after defense you will get invitation and a nice dinner for sure.

Dear Family,

My biggest gratitude goes to my Mom and dad, who supported me to chase my dream and allowed me to come to Sweden to have new experiences, not only in the research field, but also in culture and environment. I simply cannot put into words the amount of sacrifice and adjustment you have made for me during these years. If I can do even ten percent for my child, it would be a big achievement for me. I could not have achieved the PhD degree without your selfless love, support and trust in me. I hope one day I will make you feel proud. Thanks to my elder brothers **Dharmendra and Ravindra,** I know you guys have sacrificed your dream so I can achieve my dream. I will remember your contribution for the rest of my life and will try to be the person you wanted me to become. Special thanks to my Sister-in-law, **Usha**, I have no words to write your contribution to shape my future, I am lucky to have you as my sister-in-law or my first best friend with whom I could share everything without hesitation. You always helped me with everything whatever I needed. Thank you for taking care of Mom and Dad from the very first day you came to our home till now. I wish I could have helped you or share your burden to take care of the whole family. Without your guidance and encouragement I could not have reached where I am right now. Thanks for your selfless love and care and helping me emotionally and financially. My elder and younger sister, **Rinku, Mamta, Sinku** and **Lussi**, thank you for your trust and love, which gave me the courage and motivation to do better, so I can help you all to achieve your dream one day.

Lussi, Khushboo and Gaurav, you do not have to follow my path, you can choose your own path and decide what you want to be. I will always help you to achieve your goal. I would like to thank **Raushan, Saurav, Prashant, Writhwik, Rani, Raja**, and **Sanvi**. God bless you all. Thanks for making me laugh, whenever I talked to you guys. Special thanks to my brothers or best friends **Virendra** and **Shoaib**, you guys always stood by my side in every situation. Thank you for taking care of my family, when I am away from India and giving them advice instead of me. I cannot repay the love, emotion and help you guys provided over these years. I wish I can help you as selfless as you guys helped me. Thanks **to Anjali**, for your help whenever I needed. You three are my best friends forever. You guys always make me feel home, when I am Delhi.

Larissa, you have stood by my side and been a strong pillar during this PhD. Especially during these crucial five months, when I had to do a lot of work for paper revision, thesis writing, defense application and corrections of my thesis you helped me at every point. You helped me to do experiments and also taught me how to analyze FACS data. You also encouraged me by saying you can do it, I have faith in you. I am lucky to have someone smarter and broad-minded by my side like you. I am grateful to you for being by my side during the tough and stressful time of my PhD journey. Thank you for always waiting for me in the lab after finishing your work. Thank you for helping me to fix references just one night before sending for the printing, I could have not managed to finish without your help.

8 REFERENCES

1. Toker, C. Trabecular carcinoma of the skin. *Arch. Dermatol.* **105**, 107–110 (1972).

2. Kaae, J. *et al.* Merkel cell carcinoma: Incidence, mortality, and risk of other cancers. *J. Natl. Cancer Inst.* **102**, 793–801 (2010).

3. Lemos, B. & Nghiem, P. Merkel cell carcinoma: More deaths but still no pathway to blame. *Journal of Investigative Dermatology* (2007). doi:10.1038/sj.jid.5700925

4. Albores-Saavedra, J. *et al.* Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: A population based study. *J. Cutan. Pathol.* **37**, 20–27 (2010).

5. Hodgson, N. C. Merkel cell carcinoma: Changing incidence trends. *J. Surg. Oncol.* **89**, 1–4 (2005).

6. Zaar, O., Gillstedt, M., Lindelöf, B., Wennberg-Larkö, A. M. & Paoli, J. Merkel cell carcinoma incidence is increasing in Sweden. *J. Eur. Acad. Dermatology Venereol.* (2016). doi:10.1111/jdv.13698

7. Miller, N. J., Bhatia, S., Parvathaneni, U., Iyer, J. G. & Nghiem, P. Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma. *Curr. Treat. Options Oncol.* **14**, 249–263 (2013).

8. Moll, I., Kuhn, C. & Moll, R. Cytokeratin 20 is a general marker of cutaneous Merkel cells while certain neuronal proteins are absent. *J. Invest. Dermatol.* **104**, 910–915 (1995).

9. Moll, R., Löwe, A., Laufer, J. & Franke, W. W. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. *Am. J. Pathol.* **140**, 427–447 (1992).

10. Deichmann, M., Kurzen, H., Egner, U., Altevogt, P. & Hartschuh, W. Adhesion molecules CD171 (L1CAM) and CD24 are expressed by primary neuroendocrine carcinomas of the skin (Merkel cell carcinomas). *J. Cutan. Pathol.* **30**, 363–368 (2003).

11. Moll, I., Zieger, W. & Schmelz, M. Proliferative merkel cells were not detected in human skin. *Arch. Dermatol. Res.* **288**, 184–187 (1996).

12. Hausen, A. Zur, Rennspiess, D., Winnepenninckx, V., Speel, E. J. & Kurz, A. K. Early B-Cell differentiation in merkel cell carcinomas: Clues to cellular ancestry. *Cancer Research* **73**, 4982–4987 (2013).

13. Feng, H., Shuda, M., Chang, Y. & Moore, P. S. Clonal integration of a polyomavirus in human Merkel cell carcinoma. *Science* **319**, 1096–100 (2008).

14. Feng, H., Shuda, M., Chang, Y. & Moore, P. S. Clonal integration of a polyomavirus in human Merkel cell carcinoma. *Science* **319**, 1096–100 (2008).

15. Shuda, M., Kwun, H. J., Feng, H., Chang, Y. & Moore, P. S. Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator. *J. Clin. Invest.* **121**, 3623–3634 (2011).

16. Eng, T. Y. *et al.* A comprehensive review of the treatment of Merkel cell carcinoma. *American Journal of Clinical Oncology: Cancer Clinical Trials* (2007). doi:10.1097/COC.0b013e318142c882

17. Lemos, B. D. *et al.* Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system. *J. Am. Acad. Dermatol.* (2010). doi:10.1016/j.jaad.2010.02.056

18. Nicholson, S. A., McDermott, M. B., Swanson, P. E. & Wick, M. R. CD99 and cytokeratin-20 in small-cell and basaloid tumors of the skin. *Appl. Immunohistochem.* (2000). doi:10.1097/00022744-200003000-00006

19. Jaeger, T., Ring, J. & Andres, C. Histological, Immunohistological, and Clinical Features of Merkel Cell Carcinoma in Correlation to Merkel Cell Polyomavirus Status. *J. Skin Cancer* (2012). doi:10.1155/2012/983421

20. Lebbe, C. *et al.* Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. *Eur. J. Cancer* (2015). doi:10.1016/j.ejca.2015.06.131

21. Schadendorf, D. *et al.* Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. *European Journal of Cancer* (2017). doi:10.1016/j.ejca.2016.10.022

22. Schwartz, J. L. *et al.* Features predicting sentinel lymph node positivity in merkel cell carcinoma. *J. Clin. Oncol.* (2011). doi:10.1200/JCO.2010.33.4136

23. Hughes, M. P. *et al.* Merkel Cell Carcinoma: Epidemiology, Target, and Therapy. *Curr. Dermatol. Rep.* (2014). doi:10.1007/s13671-014-0068-z

24. Paulson, K. G., Iyer, J. G., Byrd, D. R. & Nghiem, P. Pathologic nodal evaluation is increasingly commonly performed for patients with Merkel cell carcinoma. *J. Am. Acad. Dermatol.* (2013). doi:10.1016/j.jaad.2013.06.002

25. Sihto, H. *et al.* Tumor infiltrating immune cells and outcome of merkel cell carcinoma: A population-based study. *Clin. Cancer Res.* (2012). doi:10.1158/1078-0432.CCR-11-3020

26. Sihto, H. & Joensuu, H. Tumor-infiltrating lymphocytes and outcome in merkel cell carcinoma, a virus-associated cancer. *OncoImmunology* (2012). doi:10.4161/onci.21120

27. Yiengpruksawan, A., Coit, D. G., Thaler, H. T., Urmacher, C. & Knapper, W. K. Merkel Cell Carcinoma: Prognosis and Management. *Arch. Surg.* (1991). doi:10.1001/archsurg.1991.01410360088014

28. Nghiem, P. *et al.* Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. *Future Oncology* (2017). doi:10.2217/fon-2017-0072

29. Arora, R. *et al.* Survivin is a therapeutic target in Merkel cell carcinoma. *Sci. Transl. Med.* **4**, 133ra56 (2012).

30. Dresang, L. R. *et al.* Response of Merkel cell polyomavirus-positive Merkel cell carcinoma xenografts to a survivin inhibitor. *PLoS One* (2013). doi:10.1371/journal.pone.0080543

31. Verhaegen, M. E. *et al.* Merkel cell carcinoma dependence on Bcl-2 family members for survival. *J. Invest. Dermatol.* (2014). doi:10.1038/jid.2014.138

32. Verhaegen, M. E. *et al.* Merkel cell polyomavirus small T antigen is oncogenic in transgenic mice. *J. Invest. Dermatol.* **135**, 1415–24 (2015).

33. M.H., S. *et al.* G3139 (Genasense) in patients with advanced merkel cell carcinoma. *Am. J. Clin. Oncol. Cancer Clin. Trials* (2009). doi:http://dx.doi.org/10.1097/COC.0b013e31817eebf8

34. Swick, B. L., Ravdel, L., Fitzpatrick, J. E. & Robinson, W. A. Merkel cell carcinoma: Evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - Implications for treatment with imatinib mesylate. *J. Cutan. Pathol.* (2007). doi:10.1111/j.1600-0560.2006.00613.x

35. Kartha, R. V. & Sundram, U. N. Silent mutations in KIT and PDGFRA and coexpression of receptors with SCF and PDGFA in Merkel cell carcinoma: Implications for tyrosine kinase-based tumorigenesis. *Mod. Pathol.* (2008). doi:10.1038/modpathol.3800980

36. Peuvrel, L., Quereux, G., Brocard, A., Renaut, J. J. & Dréno, B. Treatment of a multicentric Merkel cell carcinoma using imatinib. *Eur. J. Dermatology* (2011). doi:10.1684/ejd.2011.1527

37. Loader, D. E. *et al.* Clinical remission of Merkel cell carcinoma after treatment with imatinib. *J. Am. Acad. Dermatol.* (2013). doi:10.1016/j.jaad.2013.03.042

38. Frenard, C. *et al.* Dramatic response of an inoperable Merkel cell carcinoma with imatinib. *JAAD Case Reports* (2016). doi:10.1016/j.jdcr.2015.10.007

39. Samlowski, W. E. *et al.* A phase II trial of imatinib mesylate in merkel cell carcinoma (Neuroendocrine carcinoma of the skin): A Southwest oncology group study (S0331). *Am. J. Clin. Oncol. Cancer Clin. Trials* (2010). doi:10.1097/COC.0b013e3181b9cf04

40. Davids, M. *et al.* Response to a Novel Multitargeted Tyrosine Kinase Inhibitor Pazopanib in Metastatic Merkel Cell Carcinoma. *J. Clin. Oncol.* **27**, e97-100 (2009).

41. Ziemer, M. PD-1 blockade with pembrolizumab in advanced Merkel cell carcinoma. *Onkologe* (2016). doi:10.1007/s00761-016-0077-6

42. Kaufman, H. L. *et al.* Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. *Lancet Oncol.* **17**, 1374–1385 (2016).

43. Kaufman, H. L., Hunger, M., Hennessy, M., Schlichting, M. & Bharmal, M. Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma. *Futur. Oncol.* (2018). doi:10.2217/fon-2017-0470

44. Harms, P. W. *et al.* The distinctive mutational spectra of polyomavirus-negative merkel cell carcinoma. *Cancer Res.* **75**, 3720–3727 (2015).

45. Starrett, G. J. *et al.* Merkel Cell Polyomavirus Exhibits Dominant Control of the Tumor Genome and Transcriptome in Virus-Associated Merkel Cell Carcinoma. *MBio* (2017). doi:10.1128/mbio.02079-16

46. Goh, G. *et al.* Mutational landscape of MCPyV-positive and MCPyV-negative Merkel

cell carcinomas with implications for immunotherapy. *Oncotarget* **7**, 3403–3415 (2015).

47. Cimino, P. J. *et al.* Retinoblastoma gene mutations detected by whole exome sequencing of Merkel cell carcinoma. *Mod. Pathol.* (2014). doi:10.1038/modpathol.2013.235

48. Wong, S. Q. *et al.* UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas. *Cancer Res.* (2015). doi:10.1158/0008-5472.CAN-15-1877

49. Rodig, S. J. *et al.* Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. *J. Clin. Invest.* (2012). doi:10.1172/JCI64116

50. Park, D. E. *et al.* Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response. *Proc. Natl. Acad. Sci.* (2019). doi:10.1073/pnas.1818798116

51. Cohen, P. R. *et al.* Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics. *Oncotarget* (2016). doi:10.18632/oncotarget.8032

52. Harms, P. W. *et al.* Distinct gene expression profiles of viral- and nonviral-associated merkel cell carcinoma revealed by transcriptome analysis. *J. Invest. Dermatol.* (2013). doi:10.1038/jid.2012.445

53. Paulson, K. G. *et al.* Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral cd8+ lymphocyte invasion as an independent predictor of survival. *J. Clin. Oncol.* (2011). doi:10.1200/JCO.2010.30.6308

54. Feldmeyer, L. *et al.* Density, distribution, and composition of immune infiltrates correlate with survival in Merkel cell carcinoma. *Clin. Cancer Res.* (2016). doi:10.1158/1078-0432.CCR-16-0392

55. Miller, N. J. *et al.* Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival. *Cancer Immunol. Res.* (2017). doi:10.1158/2326-6066.cir-16-0210

56. Iyer, J. G. *et al.* Merkel cell polyomavirus-specific CD8+and CD4+ T-cell responses identified in Merkel cell carcinomas and blood. *Clin. Cancer Res.* (2011). doi:10.1158/1078-0432.CCR-11-1513

57. Lipson, E. J. *et al.* PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival. *Cancer Immunol. Res.* (2013). doi:10.1158/2326-6066.CIR-13-0034

58. Theiss, J. M. *et al.* A Comprehensive Analysis of Replicating Merkel Cell Polyomavirus Genomes Delineates the Viral Transcription Program and Suggests a Role for mcv-miR-M1 in Episomal Persistence. *PLoS Pathog.* **11**, e1004974 (2015).

59. Kwun, H. J. *et al.* The minimum replication origin of merkel cell polyomavirus has a unique large T-antigen loading architecture and requires small T-antigen expression for optimal replication. *J. Virol.* **83**, 12118–12128 (2009).

60. Houben, R. *et al.* Characterization of functional domains in the Merkel cell polyoma virus Large T antigen. *Int. J. Cancer* **136**, E290-300 (2015).

61. Hesbacher, S. *et al.* RB1 is the crucial target of the Merkel cell polyomavirus Large T antigen in Merkel cell carcinoma cells. *Oncotarget* **5**, (2016).

62. Liu, X. *et al.* Merkel cell polyomavirus large T antigen disrupts lysosome clustering by translocating human Vam6p from the cytoplasm to the nucleus. *J. Biol. Chem.* **286**, 17079–17090 (2011).

63. Feng, H. *et al.* Cellular and viral factors regulating Merkel cell polyomavirus replication. *PLoS One* **6**, (2011).

64. Nakamura, T. *et al.* Nuclear localization of Merkel cell polyomavirus large T antigen in Merkel cell carcinoma. *Virology* **398**, 273–279 (2010).

65. Cheng, J., Rozenblatt-Rosen, O., Paulson, K. G., Nghiem, P. & DeCaprio, J. A. Merkel cell polyomavirus large T antigen has growth-promoting and inhibitory activities. *J. Virol.* **87**, 6118–26 (2013).

66. Kwun, H. J. *et al.* Merkel cell polyomavirus small T antigen controls viral replication and oncoprotein expression by targeting the cellular ubiquitin ligase SCF Fbw7. *Cell Host Microbe* **14**, 125–135 (2013).

67. Pallas, D. C. *et al.* Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A. *Cell* **60**, 167–176 (1990).

68. Rodriguez-Viciana, P. *et al.* Germline Mutations in Genes Within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome. *Science (80-.).* **311**, 1287–1291 (2006).

69. Hwang, J. H. *et al.* Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation. *J. Virol.* **88**, 12055–64 (2014).

70. Shuda, M., Kwun, H. J., Feng, H., Chang, Y. & Moore, P. S. Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator. *J. Clin. Invest.* **121**, 3623–3634 (2011).

71. Griffiths, D. A. *et al.* Merkel cell polyomavirus small T antigen targets the NEMO adaptor protein to disrupt inflammatory signaling. *J. Virol.* **87**, 13853–13867 (2013).

72. Knight, L. M. *et al.* Merkel Cell Polyomavirus Small T Antigen Mediates Microtubule Destabilization To Promote Cell Motility and Migration. *J. Virol.* (2015). doi:10.1128/jvi.02317-14

73. Whitehouse, A. & Macdonald, A. Stathmin drives virus-induced metastasis. *Oncotarget* **6**, 32289–90 (2015).

74. Stakaitytė, G. *et al.* Merkel Cell Polyomavirus Small T Antigen Drives Cell Motility via Rho-GTPase-Induced Filopodium Formation. *J. Virol.* (2017). doi:10.1128/jvi.00940-17

75. Berrios, C. *et al.* Merkel Cell Polyomavirus Small T Antigen Promotes Pro-Glycolytic Metabolic Perturbations Required for Transformation. *PLoS Pathog.* (2016). doi:10.1371/journal.ppat.1006020

76. Nwogu, N. *et al.* Cellular sheddases are induced by Merkel cell polyomavirus small tumour antigen to mediate cell dissociation and invasiveness. *PLoS Pathog.* (2018). doi:10.1371/journal.ppat.1007276

77. Cheng, J., Rozenblatt-Rosen, O., Paulson, K. G., Nghiem, P. & DeCaprio, J. A.

Merkel cell polyomavirus large T antigen has growth-promoting and inhibitory activities. *J. Virol.* **87**, 6118–26 (2013).

78.   Carter, J. J. *et al.* Identification of an overprinting gene in Merkel cell polyomavirus provides evolutionary insight into the birth of viral genes. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 12744–9 (2013).

79.   Sastre-Garau, X. *et al.* Merkel cell carcinoma of the skin: Pathological and molecular evidence for a causative role of MCV in oncogenesis. *J. Pathol.* **218**, 48–56 (2009).

80.   Laude, H. *et al.* Distinct merkel cell polyomavirus molecular features in tumour and non tumour specimens from patients with merkel cell carcinoma. *PLoS Pathog.* **6**, 93–94 (2010).

81.   Borchert, S. *et al.* High-affinity Rb binding, p53 inhibition, subcellular localization, and transformation by wild-type or tumor-derived shortened Merkel cell polyomavirus large T antigens. *J. Virol.* **88**, 3144–60 (2014).

82.   Spurgeon, M. E. & Lambert, P. F. Merkel cell polyomavirus: A newly discovered human virus with oncogenic potential. *Virology* **435**, 118–130 (2013).

83.   Spurgeon, M. E., Cheng, J., Bronson, R. T., Lambert, P. F. & DeCaprio, J. A. Tumorigenic activity of merkel cell polyomavirus T antigens expressed in the stratified epithelium of mice. *Cancer Res.* **75**, 1068–1079 (2015).

84.   Houben, R. *et al.* Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. *J. Virol.* **84**, 7064–7072 (2010).

85.   Lee, R. C., Feinbaum, R. L. & Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. *Cell* **75**，843-54 (1993). doi:10.1016/0092-8674(93)90529-Y

86.   Wightman, B., Ha, I. & Ruvkun, G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. *Cell* (1993). doi:10.1016/0092-8674(93)90530-4

87.   Reinhart, B. J. *et al.* The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. *Nature* (2000). doi:10.1038/35002607

88.   Pasquinelli, A. E. *et al.* Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. *Nature* (2000). doi:10.1038/35040556

89.   Lau, N. C., Lim, L. P., Weinstein, E. G. & Bartel, D. P. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. *Science (80-.).* (2001). doi:10.1126/science.1065062

90.   Lagos-Quintana, M., Rauhut, R., Lendeckel, W. & Tuschl, T. Identification of novel genes coding for small expressed RNAs. *Science (80-.).* (2001). doi:10.1126/science.1064921

91.   Lee, R. C. & Ambros, V. An extensive class of small RNAs in Caenorhabditis elegans. *Science (80-.).* (2001). doi:10.1126/science.1065329

92.   Lee, Y. *et al.* The nuclear RNase III Drosha initiates microRNA processing. *Nature* **425**, 415–419 (2003).

93.   Sato, F., Tsuchiya, S., Meltzer, S. J. & Shimizu, K. MicroRNAs and epigenetics.

FEBS Journal **278**, 1598–1609 (2011).

94. Lee, Y., Jeon, K., Lee, J. T., Kim, S. & Kim, V. N. MicroRNA maturation: Stepwise processing and subcellular localization. *EMBO J.* **21**, 4663–4670 (2002).

95. Denli, A. M., Tops, B. B. J., Plasterk, R. H. A., Ketting, R. F. & Hannon, G. J. Processing of primary microRNAs by the Microprocessor complex. *Nature* (2004). doi:10.1038/nature03049

96. Han, J. *et al.* The Drosha-DGCR8 complex in primary microRNA processing. *Genes Dev.* **18**, 3016–3027 (2004).

97. Han, J. *et al.* The Drosha-DGCR8 complex in primary microRNA processing. *Genes Dev.* **18**, 3016–3027 (2004).

98. Okada, C. *et al.* A high-Resolution structure of the pre-microrna nuclear export machinery. *Science (80-.).* (2009). doi:10.1126/science.1178705

99. Yoda, M. *et al.* ATP-dependent human RISC assembly pathways. *Nat. Struct. Mol. Biol.* (2010). doi:10.1038/nsmb.1733

100. Sato, F., Tsuchiya, S., Meltzer, S. & Shimizu, K. MicroRNAsandepigenetics. *FEBSJournal* (2011). doi:10.1111/j.1742-4658.2011.08089.x

101. Xu, W., Lucas, A. S., Wang, Z. & Liu, Y. Identifying microRNA targets in different gene regions. *BMC Bioinformatics* (2014). doi:10.1186/1471-2105-15-S7-S4

102. Forman, J. J., Legesse-Miller, A. & Coller, H. A. A search for conserved sequences in coding regions reveals that the let-7 microRNA targets Dicer within its coding sequence. *Proc. Natl. Acad. Sci.* (2008). doi:10.1073/pnas.0803230105

103. Zhang, K. *et al.* A novel class of microRNA-recognition elements that function only within open reading frames. *Nat. Struct. Mol. Biol.* (2018). doi:10.1038/s41594-018-0136-3

104. Dharap, A., Pokrzywa, C., Murali, S., Pandi, G. & Vemuganti, R. MicroRNA miR-324-3p induces promoter-mediated expression of RelA gene. *PLoS One* (2013). doi:10.1371/journal.pone.0079467

105. Jo, M. H. *et al.* Human Argonaute 2 Has Diverse Reaction Pathways on Target RNAs. *Mol. Cell* (2015). doi:10.1016/j.molcel.2015.04.027

106. Krützfeldt, J. *et al.* Silencing of microRNAs in vivo with 'antagomirs'. *Nature* (2005). doi:10.1038/nature04303

107. Ameres, S. L. *et al.* Target RNA-directed trimming and tailing of small silencing RNAs. *Science (80-.).* (2010). doi:10.1126/science.1187058

108. Chang, Y. & Moore, P. S. Merkel cell carcinoma: a virus-induced human cancer. *Annu. Rev. Pathol.* **7**, 123–44 (2012).

109. Gandhi, M. K. Epstein-Barr virus-associated lymphomas. *Expert Review of Anti-Infective Therapy* (2006). doi:10.1586/14787210.4.1.77

110. Mesri, E. A., Feitelson, M. A. & Munger, K. Human viral oncogenesis: A cancer hallmarks analysis. *Cell Host and Microbe* (2014). doi:10.1016/j.chom.2014.02.011

111. Nassal, M. & Schaller, H. Hepatitis B virus replication--an update. *J. Viral Hepat.* **3**, 217–226 (1996).

112. Henkler F, F. & Koshy, R. Hepatitis B virus transcriptional activators: mechanisms and possible role in oncogenesis. *J. Viral Hepat.* **3**, 109–121 (1996).

113. Neuveut, C., Wei, Y. & Buendia, M. A. Mechanisms of HBV-related hepatocarcinogenesis. *J. Hepatol.* **52**, 594–604 (2010).

114. Cougot, D., Neuveut, C. & Buendia, M. A. HBV induced carcinogenesis. *J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol.* **34 Suppl 1**, S75–S78 (2005).

115. Ganem, D. KSHV and the pathogenesis of Kaposi sarcoma: Listening to human biology and medicine. *Journal of Clinical Investigation* (2010). doi:10.1172/JCI40567

116. Zhang, Z., Sun, E., Ou, J. J. & Liang, T. J. Inhibition of Cellular Proteasome Activities Mediates HBX-Independent Hepatitis B Virus Replication In Vivo. *J. Virol.* **84**, 9326–9331 (2010).

117. Jung, Y. J. *et al.* c-Myc-mediated overexpression of miR-17-92 suppresses replication of hepatitis B virus in human hepatoma cells. *J. Med. Virol.* (2013). doi:10.1002/jmv.23534

118. Scisciani, C. *et al.* Transcriptional regulation of miR-224 upregulated in human HCCs by NF??B inflammatory pathways. *J. Hepatol.* **56**, 855–861 (2012).

119. Hou, J. *et al.* Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. *Cancer Cell* **19**, 232–43 (2011).

120. Jiang, S. *et al.* A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. *The EMBO Journal* **31**, 1985–1998 (2012).

121. Wang, X. W., Heegaard, N. H. H. & Orum, H. MicroRNAs in liver disease. *Gastroenterology* **142**, 1431–1443 (2012).

122. Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M. & Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. *Science* **309**, 1577–81 (2005).

123. Janssen, H. L. *et al.* Treatment of HCV infection by targeting microRNA. *N Engl J Med* **368**, 1685–1694 (2013).

124. Lanford, R. E. *et al.* Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. *Science (80-.).* **327**, 198–201 (2010).

125. Banaudha, K. *et al.* MicroRNA silencing of tumor suppressor DLC-1 promotes efficient hepatitis C virus replication in primary human hepatocytes. *Hepatology* **53**, 53–61 (2011).

126. Murakami, Y., Aly, H. H., Tajima, A., Inoue, I. & Shimotohno, K. Regulation of the hepatitis C virus genome replication by miR-199a*. *J. Hepatol.* **50**, 453–460 (2009).

127. Bandyopadhyay, S. *et al.* Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29: miR-29 overexpression reduces hepatitis C viral abundance in culture. *J. Infect. Dis.* **203**, 1753–1762 (2011).

128. Cheng, J.-C. *et al.* Let-7b is a novel regulator of hepatitis C virus replication. *Cell. Mol. Life Sci.* **69**, 2621–33 (2012).

129. Li, S. *et al.* MicroRNA-130a inhibits HCV replication by restoring the innate immune response. *J. Viral Hepat.* **21**, 121–128 (2014).

130. Shirasaki, T. *et al.* MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells. *J. Virol.* **87**, 5270–86 (2013).

131. Pedersen, I. M. *et al.* Interferon modulation of cellular microRNAs as an antiviral mechanism. *Nature* **449**, 919–22 (2007).

132. Xu, X. *et al.* Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. *J. Clin. Invest.* **123**, 630–645 (2013).

133. Liu, F. *et al.* MiR-216b is involved in pathogenesis and progression of hepatocellular carcinoma through HBx-miR-216b-IGF2BP2 signaling pathway. *Cell Death Dis.* **6**, e1670 (2015).

134. Arzumanyan, A. *et al.* Epigenetic repression of E-cadherin expression by hepatitis B virus x antigen in liver cancer. *Oncogene* **31**, 563–72 (2012).

135. Wu, C. S. *et al.* Downregulation of microRNA-15b by hepatitis B virus X enhances hepatocellular carcinoma proliferation via fucosyltransferase 2-induced Globo H expression. *Int. J. Cancer* **134**, 1638–1647 (2014).

136. Zhang, T. *et al.* Hepatitis B virus X protein inhibits tumor suppressor miR-205 through inducing hypermethylation of miR-205 promoter to enhance carcinogenesis. *Neoplasia* **15**, 1282–91 (2013).

137. Liu, P. *et al.* HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma. *Oncotarget* **6**, 29048–29059 (2015).

138. Ura, S. *et al.* Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. *Hepatology* **49**, 1098–112 (2009).

139. Au Yeung, C. L., Tsang, T. Y., Yau, P. L. & Kwok, T. T. Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway. *Oncogene* **30**, 2401–10 (2011).

140. Wang, X. *et al.* Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. *RNA* **15**, 637–47 (2009).

141. Shi, M. *et al.* Glucocorticoid regulation of a novel HPV-E6-p53- MiR-145 pathway modulates invasion and therapy resistance of cervical cancer cells. *J. Pathol.* **228**, 148–157 (2012).

142. Cheng, S., Schmidt-Grimminger, D. C., Murant, T., Broker, T. R. & Chow, L. T. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal dlfferentiated keratinocytes. *Genes Dev.* (1995). doi:10.1101/gad.9.19.2335

143. Myklebust, M. P. *et al.* MicroRNA-15b is induced with E2F-controlled genes in HPV-related cancer. *Br. J. Cancer* **105**, 1719–25 (2011).

144. Bueno, M. J. *et al.* Multiple E2F-induced microRNAs prevent replicative stress in response to mitogenic signaling. *Mol Cell Biol* **30**, 2983–2995 (2010).

145. Liu, F. *et al.* MicroRNA-27b up-regulated by human papillomavirus 16 E7 promotes proliferation and suppresses apoptosis by targeting polo-like kinase2 in cervical cancer. *Oncotarget* **7**, (2016).

146. Melar-New, M. & Laimins, L. A. Human papillomaviruses modulate expression of microRNA 203 upon epithelial differentiation to control levels of p63 proteins. *J. Virol.* **84**, 5212–21 (2010).

147. Gunasekharan, V. & Laimins, L. A. Human papillomaviruses modulate microRNA 145 expression to directly control genome amplification. *J Virol* **87**, 6037–6043 (2013).

148. Nuovo, G. J. *et al.* Strong inverse correlation between microRNA-125b and human papillomavirus DNA in productive infection. *Diagn Mol Pathol* **19**, 135–143 (2010).

149. Jung, H. M., Phillips, B. L. & Chan, E. K. miR-375 activates p21 and suppresses telomerase activity by coordinately regulating HPV E6/E7, E6AP, CIP2A, and 14-3-3ζ. *Mol. Cancer* **13**, 80 (2014).

150. Xie, H. *et al.* MicroRNA Expression Patterns Related to Merkel Cell Polyomavirus Infection in Human Merkel Cell Carcinoma. *J. Invest. Dermatol.* **134**, 1–11 (2014).

151. Fan, K. *et al.* Circulating cell-free miR-375 as surrogate marker of tumor burden in Merkel cell carcinoma. *Clin. Cancer Res.* (2018). doi:10.1158/1078-0432.CCR-18-1184

152. Abraham, K. J. *et al.* Roles for miR-375 in neuroendocrine differentiation and tumor suppression via notch pathway suppression in merkel cell Carcinoma. *Am. J. Pathol.* **186**, 1025–1035 (2016).

153. Kumar, S. *et al.* MiR-375 Regulation of LDHB Plays Distinct Roles in Polyomavirus-Positive and -Negative Merkel Cell Carcinoma. *Cancers (Basel).* (2018). doi:10.3390/cancers10110443

154. Kumar, S. *et al.* Merkel cell polyomavirus oncoproteins induce microRNAs that suppress multiple autophagy genes. *Int. J. Cancer* (2019). doi:10.1002/ijc.32503

155. Akhbari, P., Tobin, D., Poterlowicz, K., Roberts, W. & Boyne, J. R. MCV-miR-M1 Targets the Host-Cell Immune Response Resulting in the Attenuation of Neutrophil Chemotaxis. *J. Invest. Dermatol.* (2018). doi:10.1016/j.jid.2018.03.1527

156. Deter, R. L. & De Duve, C. INFLUENCE OF GLUCAGON, AN INDUCER OF CELLULAR AUTOPHAGY, ON SOME PHYSICAL PROPERTIES OF RAT LIVER LYSOSOMES. *J. Cell Biol.* **33**, 437–449 (1967).

157. Tian, Y., Bustos, V., Flajolet, M. & Greengard, P. A small-molecule enhancer of autophagy decreases levels of Aβ and APP-CTF via Atg5-dependent autophagy pathway . *FASEB J.* (2011). doi:10.1096/fj.10-175158

158. Glick, D., Barth, S. & Macleod, K. F. Autophagy : cellular and molecular mechanisms. *J. Pathol.* **221**, 3–12 (2010).

159. Mizushima, N. Autophagy: process and function. *Genes Dev.* **21**, 2861–73 (2007).

160. Mijaljica, D., Prescott, M. & Devenish, R. J. Microautophagy in mammalian cells: Revisiting a 40-year-old conundrum. *Autophagy* (2011). doi:10.4161/auto.7.7.14733

161. Massey, A., Kiffin, R. & Cuervo, A. M. Pathophysiology of chaperone-mediated autophagy. *International Journal of Biochemistry and Cell Biology* (2004). doi:10.1016/j.biocel.2004.04.010

162. Nakatogawa, H., Suzuki, K., Kamada, Y. & Ohsumi, Y. Dynamics and diversity in autophagy mechanisms: lessons from yeast. *Nat. Rev. Mol. Cell Biol.* **10**, 458–67 (2009).

163. Chan, E. Y. Regulation and Function of Uncoordinated-51 Like Kinase Proteins. *Antioxid. Redox Signal.* (2011). doi:10.1089/ars.2011.4396

164. Walczak, M. & Martens, S. Dissecting the role of the Atg12-Atg5-Atg16 complex during autophagosome formation. *Autophagy* (2013). doi:10.4161/auto.22931

165. Burman, C. & Ktistakis, N. T. Regulation of autophagy by phosphatidylinositol 3-phosphate. *FEBS Letters* (2010). doi:10.1016/j.febslet.2010.01.011

166. Ichimura, Y. *et al.* A ubiquitin-like system mediates protein lipidation. *Nature* (2000). doi:10.1038/35044114

167. Kirkin, V., McEwan, D. G., Novak, I. & Dikic, I. A role for ubiquitin in selective autophagy. *Mol. Cell* **34**, 259–69 (2009).

168. Wirawan, E. *et al.* Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria. *Cell death Dis.* **1**, e18 (2010).

169. Takamura, A. *et al.* Autophagy-deficient mice develop multiple liver tumors. *Genes Dev.* (2011). doi:10.1101/gad.2016211

170. Mathew, R. *et al.* Autophagy Suppresses Tumorigenesis through Elimination of p62. *Cell* (2009). doi:10.1016/j.cell.2009.03.048

171. Degenhardt, K. *et al.* Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. *Cancer Cell* (2006). doi:10.1016/j.ccr.2006.06.001

172. Karantza-Wadsworth, V. *et al.* Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. *Genes Dev.* (2007). doi:10.1101/gad.1565707

173. Mathew, R., Karantza-Wadsworth, V. & White, E. Role of autophagy in cancer. *Nature Reviews Cancer* (2007). doi:10.1038/nrc2254

174. Rouschop, K. & Wouters, B. Regulation of Autophagy Through Multiple Independent Hypoxic Signaling Pathways. *Curr. Mol. Med.* (2009). doi:10.2174/156652409788167131

175. Marx, J. Autophagy: is it cancer's friend or foe? *Science (80-.).* (2006). doi:10.1126/science.312.5777.1160

176. White, E. The role for autophagy in cancer. *J Clin Invest* (2015). doi:10.1172/JCI73941

177. White, E. Deconvoluting the context-dependent role for autophagy in cancer. *Nature Reviews Cancer* (2012). doi:10.1038/nrc3262

178. Guertin, D. A. & Sabatini, D. M. Defining the Role of mTOR in Cancer. *Cancer Cell* (2007). doi:10.1016/j.ccr.2007.05.008

179. Díaz-Troya, S., Pérez-Pérez, M. E., Florencio, F. J. & Crespo, J. L. The role of TOR in autophagy regulation from yeast to plants and mammals. *Autophagy* (2008).

180. Maiuri, M. C. *et al.* Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. *Eur. Mol. Biol. Organ. J.* **26**, 2527–2539 (2007).

181. Sinha, S. & Levine, B. The autophagy effector Beclin 1: a novel BH3-only protein. *Oncogene* **27 Suppl 1**, S137–S148 (2008).

182. Balaburski, G. M., Hontz, R. D. & Murphy, M. E. P53 and ARF: Unexpected players in autophagy. *Trends in Cell Biology* (2010). doi:10.1016/j.tcb.2010.02.007

183. Feng, Z., Zhang, H., Levine, A. J. & Jin, S. The coordinate regulation of the p53 and mTOR pathways in cells. *Proc. Natl. Acad. Sci.* (2005). doi:10.1073/pnas.0502857102

184. Tasdemir, E. *et al.* Regulation of autophagy by cytoplasmic p53. *Nat. Cell Biol.* (2008). doi:10.1038/ncb1730

185. Debnath, J., Baehrecke, E. H. & Kroemer, G. Does autophagy contribute to cell death? *Autophagy* (2005). doi:10.4161/auto.1.2.1738

186. Besmer, P. *et al.* A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. *Nature* (1986). doi:10.1038/320415a0

187. Yarden, Y. *et al.* Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. *EMBO J.* (1987). doi:10.1002/j.1460-2075.1987.tb02655.x

188. Lennartsson, J. & Rönnstrand, L. Stem Cell Factor Receptor/c-Kit: From Basic Science to Clinical Implications. *Physiol. Rev.* (2012). doi:10.1152/physrev.00046.2011

189. Loveland, K. L. & Schlatt, S. Stem cell factor and c-kit in the mammalian testis: Lessons originating from Mother Nature's gene knockouts. *Journal of Endocrinology* (1997). doi:10.1677/joe.0.1530337

190. Blume-Jensen, P., Janknecht, R. & Hunter, T. The Kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. *Curr. Biol.* (2004). doi:10.1016/s0960-9822(98)70302-1

191. Babaei, M. A., Kamalidehghan, B., Saleem, M., Huri, H. Z. & Ahmadipour, F. Receptor tyrosine kinase (c-Kit) inhibitors: A potential therapeutic target in cancer cells. *Drug Design, Development and Therapy* (2016). doi:10.2147/DDDT.S89114

192. Kemmer, K. *et al.* KIT Mutations are Common in Testicular Seminomas. *Am. J. Pathol.* (2004). doi:10.1016/S0002-9440(10)63120-3

193. Corless, C. L., Fletcher, J. A. & Heinrich, M. C. Biology of gastrointestinal stromal tumors. *Journal of Clinical Oncology* (2004). doi:10.1200/JCO.2004.05.140

194. Huang, E. J., Nocka, K. H., Buck, J. & Besmer, P. Differential expression and processing of two cell associated forms of the kit-ligand: KL-1 and KL-2. *Mol. Biol. Cell* (1992). doi:10.1091/mbc.3.3.349

195. Blume-Jensen, P., Rönnstrand, L., Gout, I., Waterfield, M. D. & Heldin, C. H. Modulation of Kit/stem cell factor receptor-induced signaling by protein kinase C. *J. Biol. Chem.* (1994).

196. Yasuda, T. & Kurosaki, T. Regulation of lymphocyte fate by Ras/ERK signals. *Cell Cycle* (2008). doi:10.4161/cc.7.23.7103

197. Carlino, M. S., Todd, J. R. & Rizos, H. Resistance to c-Kit inhibitors in melanoma: insights for future therapies. *Oncoscience* (2014). doi:10.18632/oncoscience.51

198. Hirota, S. *et al.* Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. *Science (80-.).* (1998). doi:10.1126/science.279.5350.577

199. Nishida, T. *et al.* Familial gastrointestinal stromal tumours with germline mutation of the KIT gene [3]. *Nature Genetics* (1998). doi:10.1038/1209

200. Boissan, M., Feger, F., Guillosson, J. J. & Arock, M. c-Kit and c-kit mutations in mastocytosis and other hematological diseases. *Journal of Leukocyte Biology* (2000). doi:10.1002/jlb.67.2.135

201. Rossi, F. *et al.* Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. *Proc. Natl. Acad. Sci.* (2006). doi:10.1073/pnas.0511076103

202. Bosbach, B. *et al.* Imatinib resistance and microcytic erythrocytosis in of gastrointestinal stromal tumor. *Proc. Natl. Acad. Sci. U. S. A.* (2012). doi:10.1073/pnas.1115240109/-/DCSupplemental.www.pnas.org/cgi/doi/10.1073/pnas.1115240109

203. Miettinen, M. & Lasota, J. KIT (CD117): A review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. *Applied Immunohistochemistry and Molecular Morphology* (2005). doi:10.1097/01.pai.0000173054.83414.22

204. Tabone-Eglinger, S. *et al.* KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors. *Clin. Cancer Res.* (2008). doi:10.1158/1078-0432.CCR-07-4102

205. Obata, Y. *et al.* Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors. *Oncogene* (2017). doi:10.1038/onc.2016.519

206. Jaramillo, S. *et al.* Gastrointestinal stromal tumors (GISTs): role of CD 117 and PDGFRA Golgi-like staining pattern in the recognition of mutational status. *Rev. Española Enfermedades Dig.* (2012). doi:10.4321/s1130-01082012000300005

207. Kim, W. K. *et al.* Sustained mutant KIT activation in the Golgi complex is mediated by PKC-θ in gastrointestinal stromal tumors. *Clin. Cancer Res.* (2017). doi:10.1158/1078-0432.CCR-16-0521

208. Xiang, Z., Kreisel, F., Cain, J., Colson, A. & Tomasson, M. H. Neoplasia Driven by Mutant c-KIT Is Mediated by Intracellular, Not Plasma Membrane, Receptor Signaling. *Mol. Cell. Biol.* (2007). doi:10.1128/mcb.01153-06

209. Bougherara, H. *et al.* The Aberrant Localization of Oncogenic Kit Tyrosine Kinase Receptor Mutants Is Reversed on Specific Inhibitory Treatment. *Mol. Cancer Res.*

(2009). doi:10.1158/1541-7786.mcr-09-0138

210. Obata, Y. *et al.* Oncogenic Kit signals on endolysosomes and endoplasmic reticulum are essential for neoplastic mast cell proliferation. *Nat. Commun.* (2014). doi:10.1038/ncomms6715

211. Otto Warburg, B., Wind, F. & Negelein, N. THE METABOLISM OF TUMORS IN THE BODY. The Journal of General Physiology. *Biochem. Z. Biochem. Z. Biochem. Z.. Biol. Chem* (1923).

212. Porporato, P. E., Filigheddu, N., Pedro, J. M. B. S., Kroemer, G. & Galluzzi, L. Mitochondrial metabolism and cancer. *Cell Research* (2018). doi:10.1038/cr.2017.155

213. ZWERSCHKE, W. *et al.* Metabolic analysis of senescent human fibroblasts reveals a role for AMP in cellular senescence. *Biochem. J.* (2003). doi:10.1042/bj20030816

214. Heiden, M. G. Vander, Cantley, L. C. & Thompson, C. B. Understanding the warburg effect: The metabolic requirements of cell proliferation. *Science* (2009). doi:10.1126/science.1160809

215. Wallace, D. C. Mitochondria and cancer: Warburg addressed. in *Cold Spring Harbor Symposia on Quantitative Biology* (2005). doi:10.1101/sqb.2005.70.035

216. Wallace, D. C., Fan, W. & Procaccio, V. Mitochondrial Energetics and Therapeutics. *Annu. Rev. Pathol. Mech. Dis.* (2010). doi:10.1146/annurev.pathol.4.110807.092314

217. Wallace, D. C. Mitochondrial function and cancer. *Nat. Rev. Cancer* (2012). doi:10.1038/nrc3365

218. Herst, P. M., Rowe, M. R., Carson, G. M. & Berridge, M. V. Functional mitochondria in health and disease. *Frontiers in Endocrinology* (2017). doi:10.3389/fendo.2017.00296

219. Hoitzing, H., Johnston, I. G. & Jones, N. S. What is the function of mitochondrial networks? A theoretical assessment of hypotheses and proposal for future research. *BioEssays* (2015). doi:10.1002/bies.201400188

220. Palikaras, K., Lionaki, E. & Tavernarakis, N. Balancing mitochondrial biogenesis and mitophagy to maintain energy metabolism homeostasis. *Cell Death and Differentiation* (2015). doi:10.1038/cdd.2015.86

221. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. *Cell* (2011). doi:10.1016/j.cell.2011.02.013

222. Pelicano, H., Martin, D. S., Xu, R. H. & Huang, P. Glycolysis inhibition for anticancer treatment. *Oncogene* (2006). doi:10.1038/sj.onc.1209597

223. DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G. & Thompson, C. B. The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation. *Cell Metabolism* (2008). doi:10.1016/j.cmet.2007.10.002

224. NIEDERACHER, D. & ENTIAN, K. -D. Characterization of Hex2 protein, a negative regulatory element necessary for glucose repression in yeast. *Eur. J. Biochem.* (1991). doi:10.1111/j.1432-1033.1991.tb16187.x

225. Herrero, P., Galíndez, J., Ruiz, N., Martínez-Campa, C. & Moreno, F. Transcriptional regulation of the Saccharomyces cerevisiae HXK1, HXK2 and GLK1 genes. *Yeast*

(1995). doi:10.1002/yea.320110205

226. Tiefenthaler, M. *et al.* Increased lactate production follows loss of mitochondrial membrane potential during apoptosis of human leukaemia cells. *Br. J. Haematol.* (2001). doi:10.1046/j.1365-2141.2001.02988.x

227. Sheibani, S. *et al.* Inhibition of stress mediated cell death by human lactate dehydrogenase B in yeast. *FEMS Yeast Res.* (2015). doi:10.1093/femsyr/fov032

228. Asada, K. *et al.* Reduced expression of GNA11 and silencing of MCT1 in human breast cancers. *Oncology* (2003). doi:10.1159/000070297

229. Baumann, M. U., Zamudio, S. & Illsley, N. P. Hypoxic upregulation of glucose transporters in BeWo choriocarcinoma cells is mediated by hypoxia-inducible factor-1. *Am. J. Physiol. Physiol.* (2007). doi:10.1152/ajpcell.00075.2007

230. Brizel, D. M. *et al.* Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. *Int. J. Radiat. Oncol. Biol. Phys.* (2001). doi:10.1016/S0360-3016(01)01630-3

231. Chang, Y. *et al.* MiR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions. *Gastroenterology* **143**, (2012).

232. Zhu, H. *et al.* Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells. *Autophagy* **5**, 816–23 (2009).

233. Kumar, S. *et al.* Overexpression of microRNA-30a inhibits hepatitis B virus X protein-induced autophagosome formation in hepatic cells. *FEBS J.* (2015). doi:10.1111/febs.13209

234. Giebel, L. B., Strunk, K. M., Holmes, S. A. & Spritz, R. A. Organization and nucleotide sequence of the human KIT (mast/stem cell growth factor receptor) proto-oncogene. *Oncogene* (1992).

235. Su, L. D. *et al.* CD117 (KIT receptor) expression in Merkel cell carcinoma. *Am. J. Dermatopathol.* (2002). doi:10.1097/00000372-200208000-00001

236. Caplan, S., Hartnell, L. M., Aguilar, R. C., Naslavsky, N. & Bonifacino, J. S. Human Vam6p promotes lysosome clustering and fusion in vivo. *J. Cell Biol.* (2001). doi:10.1083/jcb.200102142

237. Wei, Y. *et al.* XEGFR-mediated beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. *Cell* (2013). doi:10.1016/j.cell.2013.08.015

238. Lee, Y. *et al.* Increased SCF/c-kit by hypoxia promotes autophagy of human placental chorionic plate-derived mesenchymal stem cells via regulating the phosphorylation of mTOR. *J. Cell. Biochem.* (2013). doi:10.1002/jcb.24303

239. Shao, Q. A Proteomic Study of Human Merkel Cell Carcinoma. *J. Proteomics Bioinform.* (2013). doi:10.4172/jpb.1000291

240. Richards, K. F. *et al.* Merkel cell polyomavirus T antigens promote cell proliferation and inflammatory cytokine gene expression. *J. Gen. Virol.* (2015). doi:10.1099/jgv.0.000287

241. Matsui, H., Asou, H. & Inaba, T. Cytokines Direct the Regulation of Bim mRNA

Stability by Heat-Shock Cognate Protein 70. *Mol. Cell* (2007). doi:10.1016/j.molcel.2006.12.007